
Title: A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy 
and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)
Study ID: [REMOVED]
Protocol Approve Date: 14 September 2020
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.0 T ITLE PAG E
PROTOCOL AMENDMENT
A Randomized, Double -Blind, Placebo -Controlled Phase 4 Study to Evaluate the Efficacy 
and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)
Vedolizumab IV 300 mg in the Treatment of Chronic Pouchitis
Sponsor: Takeda Development Center Americas, Inc.
One Takeda Parkway
Deerfield, IL 60015
Takeda Development Centre Europe, Ltd.
61 Aldwych
London, WC2B 4AE
United Kingdom
Study Number: Vedolizumab -4004
IND Number: 009125 EudraCT Number: 2015-003472-78
Compound: Vedolizumab IV
Date: 14September 2020 Amendment Number: 04
Amendment History : 
Date Amendment Number Amendment Type Region
12 February 2016 Initial Protocol Not applicable Global
01 June 2016 01 Non-substantial Global
20 October 2016 02 Substantial Global
21 April 2017 03 Substantial Global
14September 2020 04 Non-substantial Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 2 of 107Protocol Incorporating Amendment No. 04 14 September 2020
1.0 ADMINISTRATIVE INFORMATION 
1.1 Contacts 
A separate contact information list will be provide d to each site.
Takeda Development Center (TDC) sponsored investigators per individual country requirements 
will be provided with emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section  3.1and relevant guidelines 
provided to the site.
Contact Type/RoleUnited States/Canada
ContactEurope/Rest of World
Contact
Serious adverse event and 
pregnancy reporting
Medical Monitor
(medical advice on protocoand compound)
Responsible Medical 
Officer (carries overall responsibility for the conduct of the study)PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useuiuiremenremeiiii
each subeach s
ssignesigne d
nt guidet guid
Europe/REuropeA
cial Use Only and Subject to 
Vedolizumab IV
Study No. Vedolizumab-4004 Page 3 of 107Protocol Incorporating Amendment No. 04 14 September 2020
1.2 Approval
REPRESENTATIVES OF TAKEDA This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can
be found on the signature page.
Electronic Signatures may be found on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedance ance
olidatedlidate
a privacpriva
other sigther s
thihis docs do
: For Non-Commercial Use Only and
Vedolizumab IV
Study No. Vedolizumab-4004 Page 4 of 107Protocol Incorporating Amendment No. 04 14 September 2020
1.3 Protocol Amendment 04 Summary of Changes
Rationale for Amendment 04This document describes the changes in reference to the Protocol Incorporating Amendment 
No. 04.
The primary reason for this amendment is to add exploratory objectives and endpoints for the 
Minor grammatical, editorial and form atting changes, for clarif ication purposes only, are not listed
below nor in  Appendix J. For specific description of text changes and where the changes are 
located, see  Appendix J.
Changes in Amendment 04
3. Added centrally read endoscopic assessments of the pouch.
7. Clarified that prior medication history includes all prior med ications for the tr eatment of 
UC/pouchitis.
8. Corrected acute histologic inflammation de scriptors for score of 0 in Appendix E for 
clarification of PDAI scoring.
9. Deleted duplicated text describing analysis set for primary analysis. CCI
CCI
CCI
Property of Takeda: fied thated tha
C/Cpouchpouc/
CoCorre
clclar
9.9ly and Subjecrificatificat io
changechangble Terms of Usent n
nts s fofor t
ect to the Applicable
ommercial Use OnlyComendndososco
a: For Non-C
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 5of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
INVE STIGATOR AGRE EMENT
I confirm that I h ave read and that I understand this pr otocol , theInvest igator’s Brochure, the 
vedo lizumab IV (Entyvio) pack age ins ertandany other product infor mation provided by the 
sponsor. I agree to conduct this study in acc ordance with the requi rements of this prot ocolandalso 
to protect the rights, s afety , privacy, and well -being of study  subjects in accordance wit h the 
following:
The ethica l principles th at have their origin in the Declaration of He lsinki.
International C onference on Harm onisa tion, E6 Good Clinic al Practice: Conso lidated 
Guideline.
All appli cable laws and regulat ions, including, without limitat ion, dat a priva cy lawsand 
regulations.
Regula tory requi rements for reporting serious adver se events defined in Se ction10.2 of this 
protocol .
Terms outlined inthe Clinical Study  Site Agreement.
Responsibilit ies o f theInvest igator (Appendix B).
I further aut horize that my personal information may be pr ocessed and transfer red in accordance 
with the uses contem plated i n Appendix Dof thisprotoc ol.
Signatur e of Investigat or Date
Invest igator Name (print or ty pe)
Invest igator’s Ti tle
Locati on of  Facility (Ci ty, State /Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 6of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
TABLE OF CONTENTS
1.0 ADMINIST RATIVE INFORMATION ........................................................................... 2
1.1 Contact s..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 04 Summary  of Changes .......................................................... 4
2.0 STUDY SUMMARY .................................................................................................... 12
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 16
3.1 Study -Related Responsibilit ies................................................................................. 16
3.2 Principa l Invest igator/Coordinating Inv estigator ...................................................... 16
3.3 Listof Abbreviat ions............................................................................................... 17
3.4 Corporate Identificat ion........................................................................................... 19
4.0 INTRODUCTION ......................................................................................................... 20
4.1 Background ............................................................................................................. 20
4.1.1 Disease and Current T reatm ents for Chronic or Recurre nt Pouchit is................... 20
4.1.2 Vedolizumab ...................................................................................................... 21
4.1.2.1 Nonclinical ................................................................................................... 22
4.1.2.2 Human Experience ....................................................................................... 22
4.2 Rationale for the Proposed S tudy............................................................................. 23
4.3 Benefit -Risk Assessment ......................................................................................... 23
5.0 STUDY OB JECTIVES A ND ENDPOINTS .................................................................. 25
5.1 Object ives................................................................................................................ 25
5.1.1 Prima ry Object ive.............................................................................................. 25
5.1.2 Secondary  Object ives......................................................................................... 25
5.1.3 Exploratory  Objectives ....................................................................................... 25
5.1.4 SafetyObjective .................................................................................................26
5.2 Endpoints ................................................................................................................. 26
5.2.1 Primary Endpo int............................................................................................... 26
5.2.2 Second ary Endpo ints.......................................................................................... 26
5.2.3 Exploratory  Endpo ints....................................................................................... 26
5.2.4 Safety Endpo ints................................................................................................ 27
6.0 STUDY DESIGN AND DE SCRIPTION ....................................................................... 28
6.1 Study  Design ........................................................................................................... 28
6.2 Justification for Study Design, Dose, and Endpoin ts................................................ 29
6.3 Prem ature Termi nation or Suspension o f Study  or Study  Site................................... 29
6.3.1 Criteria for Premature Terminat ion or Suspension of th eStudy .......................... 29
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 7of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
6.3.2Criteria for Prematur e Terminat ion or Suspension of Study  Sites....................... 30
6.3.3 Procedures for Premature Termination or Sus pension of th e Stu dy or the 
Parti cipation of  Study  Site(s)................................
.............................................. 30
7.0 SELECTION AND DISCONTIN UATION/W ITHDRAWAL OF SUBJECT S.............. 31
7.1 Inclu sion Cri teria..................................................................................................... 31
7.2 Exclusion Criteria.................................................................................................... 31
7.2.1 Gastrointestinal Exclusio n Cri teria..................................................................... 32
7.2.2 Infectious Disease Exc lusio n Cri teria................................ .................................32
7.2.3 General Exclusio n Cri teria................................................................................. 33
7.3 Excluded Medicat ions.............................................................................................. 34
7.3.1 Permi tted Me dicat ions and Treatm ents............................................................... 35
7.3.1.1 Oral Corti costeroi d Dosing and Tapering ..................................................... 36
7.4 Criteria for Di scontinuation or Withdrawal o f a Subject ........................................... 36
7.5 Procedu res for Discont inuat ion or Withdrawal o f a Subject ...................................... 37
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ...................................................... 38
8.1 Study  Drug and Materials ........................................................................................ 38
8.1.1 Dosage Form, Manufacturing, Packa ging, and Lab eling ..................................... 38
8.1.1.1 Vedolizumab IV and Placebo ....................................................................... 38
8.1.1.2 Com panion Medicati on................................................................................ 38
8.1.2 Storage ............................................................................................................... 38
8.1.3 Dose and Regimen ............................................................................................. 38
8.1.4 Overdose ............................................................................................................ 39
8.2 Study Drug Assignment and Di spensing Procedures ................................................ 39
8.3 Randomization Code Creati on and Storage .............................................................. 40
8.4 Drug Blind M aintenance .......................................................................................... 40
8.5 Unblind ing Procedure ................................ .............................................................. 40
8.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 40
9.0 STUDY PLAN .............................................................................................................. 42
9.1 Study  Procedures ..................................................................................................... 42
9.1.1 Inform ed Consent Procedure .............................................................................. 42
9.1.2 Dem ographics, Med ical Histo ry, and Me dicat ion History  Procedure .................. 42
9.1.3 Ulcerat ive Co litis and Pouchit is History ............................................................. 42
9.1.4 Physi cal Examinat ion Procedure ........................................................................ 42
9.1.5 Weight, Height ................................................................................................... 43
9.1.6 Vital Sign Procedure .......................................................................................... 43
9.1.7 PML Checklis t................................................................................................... 43
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 8 of 107Protocol Incorporating Amendment No. 04 14 September 2020
9.1.8 ECG Proced ure ..................................................................................................43
9.1.9 Primary Efficacy Measuremen t ..........................................................................43
9.1.10 Pouchitis Endoscopy ..........................................................................................43
9.1.11 PDAI .................................................................................................................44
9.1.129.1.139.1.14 Patient Reported Outcome Measures..................................................................45
9.1.14.1 IBDQ .....................................................................................................45
9.1.14.2 Cleve land Global Quality of Life (C GQL) instrument (F azio Score ).......45
9.1.15 Documentation of Concomitant Medi cations......................................................45
9.1.16 Documentation of Concurrent Medical Conditions .............................................45
9.1.17 Procedures for Clinical La boratory Sa mples .......................................................46
9.1.189.1.19 Clostridium Difficile Sample Collection .............................................................47
9.1.20 Tuberculosis Screening ......................................................................................47
9.1.21 Contraception and Pregnancy Avoidance Procedure ...........................................47
9.1.21.1 Male Subjects and Their Female Partners ...............................................47
9.1.21.2 Female Subjects and Their Male Pa rtners ...............................................47
9.1.21.3 Definitions and Procedures for Contraception and Pregnancy 
Avoidance....................................................................................................48
9.1.21.4 General Guidance With Respect to the Avoidance of Pregnancy .............50
9.1.22 Pregnanc y ..........................................................................................................50
9.1.23 Documentation of Screen Failure .......................................................................509.1.24 Documentation of Randomization ......................................................................51
9.2 Monitoring Subject Tr eatment Compliance..............................................................51
9.3 Schedule of Observation s and Proce dures ................................................................51
9.3.1 Screenin g ...........................................................................................................51
9.3.2 Rescreenin g .......................................................................................................51
9.3.3 Study Rando mization .........................................................................................52
9.3.4 End of Tr eatment Visit .......................................................................................52
9.3.5 Final Endoscopy Visit or Early Termination.......................................................52
9.3.6 Safety Follow- Up Visi t ......................................................................................52
9.3.7 Post-St udy Follow-Up ........................................................................................52
9.3.8 Unscheduled Visits Due to Exacerbation/Relapse of Pouchitis ...........................52
9.3.9 Post-S tudy Care .................................................................................................53
10.0 PRETREATMENT EVENTS (PTE) AND ADVERSE EVEN TS (A E) .........................54CCI
CCICCI
Property of Takeda: For Non-Commercial Use Only and Su...............
............
idance dance
irFemaFem
d Their d The
ProceduProced
.............
Guidancuidan
.............
atition ofon 
mentntatiato
oring Suing S
edule oedule
1ScreSc
9.3.2.3.2bject to the Applicabl.............
..............
ent (Fazt (Faz
..................
..............
.............Terms of Use433
.........4444
9.3.39.3
9ble T
SubjeTerm
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 9of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
10.1 Definit ions............................................................................................................... 54
10.1.1 PTEs .................................................................................................................. 54
10.1.2 AEs.................................................................................................................... 54
10.1.3 Product Complaint s............................................................................................ 54
10.1.4 Addi tional Po ints to Co nsider for PTEs and AEs ................................................ 54
10.1.5 SAEs .................................................................................................................. 56
10.1.6 AEs of S pecial Interest ....................................................................................... 57
10.1.7 Intensit y of PTEs and AEs ................................................................................. 59
10.1.8 Causalit y of AEs................................................................................................ 59
10.1.9 Relationship to Study  Procedures ....................................................................... 59
10.1.10 Start Da te..................................................................................................... 59
10.1.11 Stop Da te..................................................................................................... 59
10.1.12 Frequency .................................................................................................... 59
10.1.13 Action Concerning Study  Drug .................................................................... 59
10.1.14 Outcom e....................................................................................................... 60
10.2 Procedures ............................................................................................................... 60
10.2.1 Collect ion and Re porti ng of AEs........................................................................ 60
10.2.1.1 PTE and AE Collection Period ............................................................... 60
10.2. 1.2 PTE and AE Reporting ........................................................................... 61
10.2.1.3 AEs of Special Interest ........................................................................... 61
10.2.2 Collect ion and Reporti ng of SAEs ...................................................................... 61
10.2.3 Reporting of Abnormal Li ver Functi on Tests ..................................................... 62
10.3 Follow-Up of SAEs .................................................................................................62
10.3.1 Safety Reporting to Invest igators, I RBs or IECs, and Regulatory  Authorities.....62
11.0 STUD Y
-SPECIFIC COMMITTEES ............................................................................. 64
11.1 Steering Committee .................................................................................................64
11.2 Adjudicat ion Co mmittee .......................................................................................... 64
11.2.1 Risk Assessment and Min imizat ion Act ion Plan for PML (RAMP) Program ......64
12.0 DAT A HANDLING A ND RECORDK EEPING ............................................................ 66
12.1 eCRFs ................................ ...................................................................................... 66
12.2 Record Retent ion..................................................................................................... 66
13.0 STATIS TICAL METH ODS .......................................................................................... 68
13.1 Statistical and Analyt ical Plans ................................................................................ 68
13.1.1 Anal ysis Sets...................................................................................................... 68
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 68
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 10of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
13.1.3 Efficacy Analysis ............................................................................................... 68
13.1.4 Safety Analysis .................................................................................................. 69
13.2 Futility Analysis and Criteria for Early Terminat ion................................................ 69
13.3 Dete rminat ion of Sample Size .................................................................................. 70
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 71
14.1 Study -Site Moni toring Visit s................................................................................... 71
14.2 Protocol  Dev iations.................................................................................................. 71
14.3 Quali ty Assurance Audi ts an d Regulatory  Agency  Inspect ions................................ 71
15.0 ETHICAL ASPECTS OF THE STUDY ........................................................................ 72
15.1 IRB and/or IEC Approval ........................................................................................ 72
15.2 Subject Informat ion, Inform ed Conse nt, and Subj ect Aut horization......................... 73
15.3 Subject Confidentialit y............................................................................................ 74
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Polic y.................................74
15.4.1 Publication and Discl osure ................................................................................. 74
15.4.2 Clinical Trial Registration .................................................................................. 75
15.4.3Clinical Tri al Resul ts Discl osure........................................................................ 75
15.5 Insurance and Co mpensation for Injury .................................................................... 75
16.0 REFERENCES .............................................................................................................. 76
LIST OF IN -TEXT T ABLES
Table 8.a Dose and Regimen ................................
............................................................. 39
Table 9.a Clinical Laboratory  Tests ................................................................................... 46
Table 10.a Takeda Medically Significant AE List................................................................ 57
LIST OF IN -TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 29
LIST OF APPENDICES
Appendix A Schedule of Study  Procedures ............................................................................ 80
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 82
Appendix CElements of the Subject Informed Consent ......................................................... 84
Appendix D Invest igator Consent to Use of Personal Informat ion.......................................... 87
Appendix E The Pouchit is Disease Activity Index (PDAI) .................................................... 88
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 11 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Appendix F The Modified Pouchitis Disease Activity Index (mPDAI) ..................................89
Appendix GAppendix HAppendix I Inflammatory Bowel Dis ease Questionna ire (IB DQ)..........................................92
Appendix J Detailed Description of Amendments to Text ...................................................102CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use.........9292
................ 1so
Vedolizumab IV
Study No. Vedolizumab-4004 Page 12 of 107Protocol Incorporating Amendment No. 04 14 September 2020
2.0 STUDY SUMMARY
Name of Sponsor(s):
Takeda Development Center Americas, Inc.
Takeda Development Centre Europe, LtdCompound:
Vedolizumab IV
Title of Protocol: A Randomized, Double-Blind,
Placebo- Contro lled Phase 4 Study to Evaluate the Efficacy 
and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)IND No.: 009125 EudraCT No.:
2015-003472-78
Study Number: Vedolizumab-4004 Phase: 4
Study Design:
Phase 4, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vedolizumab
300 mg intravenous (IV) infusion during a 34-week treatment period (with last dose at Week 30) using pouch endoscopy. Approximately 110 subjects with a procto colectomy and ileal pouch anal anastomosis (IPAA) for 
ulcerative colitis (UC) who have developed c hronic or recurrent pouchitis will be enrolled. 
Chronic or recurrent pouchitis is defined as a modified Pouchitis Disease Activity Index (mPDAI) score ≥5 assessed 
as the average from 3 days immediately prior to the Bas eline endoscopy and a minimum endoscopic subscore of 2 
(outside the staple or suture line) with either:
(a) ≥3 recurrent episodes within 1 year prior to the Screening visit, each treated with ≥2 weeks of antibiotic or other 
prescription therapy, or 
(b) requiring maintenance antibiotic therapy taken continuously for ≥4 weeks immediately prior to the Baseline 
Endoscopy Visit.
Subjects will be randomized in a 1:1 ratio to either the approved UC vedolizumab dose regimen or placebo treatment 
at Day 1, Weeks 2, 6, 14, 22, and 30. All subjects will r eceive concomitant antibiotic treatment with ciprofloxacin 
500 mg twice daily from randomization through Week 4. Efficacy will be assessed at Week 14 and Week 34. 
Primary Objective:
To compare the efficacy of vedolizumab IV and placebo in terms of the percentage of subjects with chronic or 
recurrent pouchitis achieving clinically relevant remission.
Secondary Objectives:
To assess the efficacy of vedolizumab IV by:
!Percentage of subjects achieving mPDAI <5 and a reduction of overall score by ≥2 points from Baseline.
!Percentage of subjects achieving PDAI <7 and a reduction of overall score by ≥3 points from Baseline.
!Time to remission (defined as a PDAI score <7 and a decrease in PDAI score of ≥3 points from Baseline).
!Percentage of subjects achieving a partial response (defined as reduction of mPDAI score by ≥2 points from 
Baseline).
!Change in PDAI endoscopic subscore.
!Change in PDAI histologic subscore.
!Change in total PDAI.
!Change in Inflammatory Bowel Disease Questionnaire (IBDQ), and Cleveland Global Quality of Life (CGQL, 
Fazio Score, 3 items).
Exploratory Objectives:
CCIdolizumaolizum
cts achiects achi
ubjects acubjects 
mission (dssion 
age of sube of su
ine).ine).
hange inhange i
ChangCha
!!Ch
!!ommerciaab IV anb IV a
ally rellly rel evial Use Only and Subject to the Applicable Terms of Useofof
:
722-78-7rm
ica
and d safetysaf
eat Weeat We
anal anaanal an
l be enrobe en
Activity Activity
yand a and a 
sit, et, eachach
uously foously 
heeaapppr
s willwillrer
gh Weekh Weepp
ia
om
pepe
Vedolizumab IV
Study No. Vedolizumab-4004 Page 13 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Safety Objective:
To assess the safety of vedolizumab IV in chronic or recurrent pouchitis.
Subject Population: Adult subjects with a proctocolectomy and IPAA for UC, that was completed at least 1 year 
before the Day 1 (Randomization) Visit, who have develope d chronic or recurrent pouchitis, defined as a mPDAI
score ≥5 assessed as the average from 3 days immediately prior to the Baseline endoscopy and a minimum endoscopic 
subscore of 2 (outside the staple or suture line) with either:
(a) ≥3 recurrent episodes within 1 year prior to the Screening visit,  each treated with ≥2 weeks of antibiotic or other 
prescription therapy, or
(b) requiring maintenance antibiotic therapy taken continuously for ≥4 weeks immediately prior to the Baseline 
Endoscopy Visit
Number of Subjects:
Approximately 110 subjects will be  randomly assigned in a 
1:1 ratio to receive vedolizumab IV (n=55) or placebo (n=55).Number of Sites: 
Approximately 40 sites in North America and Europe.
Dose Level(s):
Group 1: Vedolizumab IV 300 mg at Day 1, Weeks 2, 6, 14, 
22, and 30.
Group 2: Placebo IV at Day 1, Weeks 2, 6, 14, 22, and 30. 
All subjects will receive ciprofloxacin 500 mg twice daily 
through Week 4.Route of Administration:
Intravenous
Duration of Treatment:
34 weeks (with last dose at Week 30)Period of Evaluation:
The study includes up to a 4-week Screening Period, a 
34-week Treatment Period (with last dose at Week 30), 
and an 18-week Follow-up Period following last dose. The duration of the study from the start of screening to 18 weeks post last dose at Week 30 will be approximately 52 weeks. All subjects will participate in a long-term follow-up (LTFU) safety survey by telephone 26 weeks after their last dose.
Main Criteria for Inclusion:
!Male or female subjects aged 18 to 80 years, inclusive.
!History of IPAA for UC completed at least 1 year prior to the Day 1 (Randomization) Visit.
!Pouchitis that is chronic or recurrent, defined by an mPDAI score ≥5 assessed as the average from 3 days 
immediately prior to the Baseline endoscopy and a minimum endoscopic subscore of 2 (outside the staple or suture line) with either (a) ≥3 recurrent episodes within 1 year prior to the Screening Period treated with ≥2 weeks 
of antibiotic or other prescription therapy, or (b) requiring maintenance antibiotic therapy taken continuously for≥4 weeks immediately prior to the Baseline Endoscopy Visit.
Main Criteria for Exclusion:
!Crohn’s disease (CD), CD of the pouch, irritable pouch syndrome (IPS), isolated or predominant cuffitis, 
diverting stoma, or mechanical complications of the pouch. 
!Previous treatment with vedolizumab, natalizumab, efalizumab, rituximab, etrolizumab, or anti-mucosal CCI
Property of Takeda:ia for Ina for I
e or femaor fem
Historistory yoa: For Non-Commercial Use Only and Subject to the Applicable Terms of Useofof
d at at lleaeast 
ined as aned as 
a minima minim
2 weeks oweeks 
mmediatelmediatle
Sites: Sites: 
imately imately 44ec
14, 14, 
and 30. and 30
twice dawice dRoute Rout
IntrInan
nl
)ci
PouchPou
ima: 
pepe
Vedolizumab IV
Study No. Vedolizumab-4004 Page 14 of 107Protocol Incorporating Amendment No. 04 14 September 2020
addressin cell adhesion molecule -1 (MAdCAM-1) therapy.
!Any investigational or approved biologic or bi osimilar agent within 60 days of randomization.
!Nonbiologic investigational therapy within 30 days prior to randomization. 
!Active or latent tuberculosis.
!Chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection or a known history of 
human immunodeficiency virus (HIV) infection (or is found to be seropositive at Screening) or subject is immunodeficient.
!Active, severe infection.
!Positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist at Screening.
Main Criteria for Evaluation and Analyses:
The primary efficacy endpoint is the percentage of subjects with chronic or recurrent pouchitis achieving clinically 
relevant remission after 14 weeks of treatment. Clinically relevant remission will be defined as an mPDAI score <5 and a reduction in overall score by ≥2 points from Baseline.
Secondary efficacy endpoints are:
!Percentage of subjects achieving mPDAI score <5 and a reduction of overall score by ≥2 points from Baseline 
after 34 weeks of treatment (last dosing at week 30).
!Percentage of subjects achieving PDAI score <7 and a reduction of overall score by ≥3 points from Baseline 
PDAI score after 14 weeks of treatment and after 34 weeks of treatment (last dosing at Week 30).
!Time to remission (defined as a PDAI score <7 and a decrease in PDAI score of ≥3 points from Baseline).
!Percentage of subjects achieving a partial response (defined as a reduction in mPDAI score by ≥2 points from 
Baseline) after 14 and after 34 weeks of treatment (last dosing at week 30).
!Change in PDAI endoscopic subscore at Weeks 14 and 34 compared to Baseline.
!Change in PDAI histologic subscore at Weeks 14 and 34 compared to Baseline.
!Change in total PDAI score at Weeks 14 and 34 compared to Baseline.
!Change in IBDQ, and CGQL (Fazio Score, 3 items) at Weeks 14, 22, and 34 compared to Baseline.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Apppouchitisouchit
e defineddefin
f overallf overa
ion of ovn of o
s of treatof trea
ecrease ecrease
(de(defifinedne
nt (last dt (last 
eks 14 aneks 14pplicable Terms of Usestory of story of
bject is ect is 
ist at Scrt at Scofof
Weeks 14Weeks
s 14 and 14 an
azio Scorio Scopp
pepeperty of Takeda: For Non-Comm
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 15of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Safety  will be assessed by adverse events (AEs), adverse events of special interest (AESI s), ser ious adverse e vents 
(SAEs), vita l signs, and results of standard l aborato ry tests (clinic al chemi stry, hematology, coagulation, and
urinal ysis).
Statistical Considerations:
The primary efficacy endpoint is the percentage of subjects who achieve cli nically relevant remi ssion at Week 14 
(defined as an mPDAI score <5 and a decrease in mPDAI scor e of ≥2 points from Baseline). Subjects w ho withdraw 
early  for any reasons will be included in the denominator for the estimation of this percentage. At the fin al analysis, the 
difference between the percentages of subjects achieving remission at Week 14 i n each treatment group will be 
assessed by the chi -squared test. The null hypothesis, that the percentage of subjects achieving remission at Week 14 
in each tre atment group is the s ame, will be teste d against the alternative hypothes is that the 2 percentag es are not the 
same.
The primary efficacy analysis will be based on the full analysis set (FAS) including all randomized subjects. Analysis 
will also be perform ed on t he PP populati on for confirmator y purposes. 
Thesecondary endpoin t of time to remission (defined as a PDAI score <7 and a decrease in PDAI score of ≥3 points 
from Baseline), will be analyzed by survival analysis procedures. Remission rates from the time o f randomizatio nover 
the 34 -week study period will be estimated by Kaplan-Meier product l imit methods. The log -rank test will be applied 
to compare the 2 treatment groups. Cox proportional hazards regression will be performed to explore the effect o f
progn ostic factors. Adjustments for b aseline imbalances on key prognost ic factors will be made using Cox regression. 
As this is a multicenter clinical study, heterogeneity of treatment effect across the participating centers will be 
explored. 
Statistica ltests will be 2 -side d and performed a t the 0.05 level of significance.
A single futility analy sis will be performed when 25 patients per treatment arm have been recruited and completed 
their Week 14 assessment for primary efficacy. The purpose of this an alysis will be to ass ess for futility, and at this 
point simulations will beperformed to determ ine the posterior probability of achieving a treatment difference of at 
least 25% between the active and placebo treatment arms. On the basis of the posterior p robabil ity of success ,a 
decision will be made to continue or terminate t he study on the grounds of futility. It is not intended to stop the study 
on the grounds of efficacy; hence, no adjustment to the statistical significance level used for testing at thefinal analy sis 
is necessary.
Safety a nalyses will be based on the safet y (SAF) analysis set. A ll subjects who received at least 1 dose of study drug 
will be included in the safety analysis s et. No formal statistical tests will be performed for safety ana lyses.
Sample Size J ustification: 
Thesample size is calculated on the basis of remission rate at 14 weeks. The remission rate in subjects treated with 
placebo is estimated to be 15%. An effect size of at least 25% would be considered clinically meaningf ul (ie, a 
remission r ate of 40% in subj ects maintained on vedolizumab IV) .
Therefore, a total of 98 evaluable subjects (49 per 
treatment group) will be required to detect a 25% difference in the remission rate at the 2 -sided 0.05 level of 
significance with 80% po wer. To accoun tfor attrition, 1 10 subjects will be randomized (55 per treatment group).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 16of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the
Study -Related Respo nsibilit ies docume nt. The vendors identified in the template for specific 
study-related activit ies will perform  these act ivities in full or in partnership with the sponsor.
3.2 Principal Investigator/Coordinating Investigator 
Takeda will select a Signatory  Coordinating Investi gator fro m the invest igators who p articipate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study  drug, their expert ise in the therapeutic area and the conduct of clini cal research 
as we ll as study  parti cipati on. The Si g
natory Coordinat ing Inv estigator will be required to review 
and sign the clinical study  report and by doing so agrees that it accurately describes the results of 
the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 17 of 107Protocol Incorporating Amendment No. 04 14 September 2020
3.3 List of Abbreviations
5-ASA 5-aminosalicylate
6-MP 6-mercaptopurine
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferaseAST aspartate aminotransferase
ATZ anal transitional zone
eCRF electronic case report form
CD Crohn’s disease
CGQL Cleveland Global Quality of Life
CIMS Central Image Management Solutions
CRA clinical research associateCRO
contract research organization
ECG electrocardiogram
EMA European Medicines Agency
EOS end of studyEOT end of treatment 
ET early termination
FAP familial adenomatous polyposis
FAS full analysis set
FDA Food and Drug AdministrationFSH follicle-stimulating hormone
G6PD glucose-6-
phosphate dehydrogenase
GALT gut-associated lymphoid tissue
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GI gastrointestinal
HBsAg hepatitis B virus surface antigenhCG human chorionic gonadotropin
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
HRQOL health-related quality of lifeIAC Independent Adjudication Committee
IBD inflammatory bowel disease
IBDQ Inflammatory Bowel Disease Questi onnaire
IB Investigator’s Brochure
ICH International Conference on HarmonisationCCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useus polypus poly
rug Admg Adm
stimulatinmulat
oseose--66--phop
ut-associasso
Good Good
ga
V
HIVIV
HRQHRQ
IA
Vedolizumab IV
Study No. Vedolizumab-4004 Page 18 of 107Protocol Incorporating Amendment No. 04 14 September 2020
IEC independent ethics committee
IgG1 immunoglobulin G1
INR international normalized ratio
IPAA ileal pouch anal anastomosis
IPS irritable pouch syndrome
IRB institutional review boardIRR infusion-related reaction
IV intravenous
IWRS interactive web response system
JCV John Cunningham virus
LFT liver function testsLTFU long-term follo
w-up
mAb monoclonal antibody
MAdCAM-1 mucosal addressin cell adhesion molecule-1
Med ID medication identification number
MedDRA Medical Dictionary for Regulatory Activities
mPDAI modified Pouchitis Disease Activit yIndex
PC product com plaint
PD pharmacodynamics
PDAI Pouchitis Disease Activity Index
PK pharmacokinetics
PML progressive multifocal leukoencephalopathy
PP per-protocol 
PTE pretreatment event
Q8W once every 8 weeks
RAMP Risk Minimization Action Plan for PML
SAE serious adverse event
SAF safety analysis set
SAP statistical analysis plan
SPC Summary of Product Characteristics
SUSAR suspected unexpected serious adverse reactions
TB Tuberculosis
TEAE treatment-emergent adverse eventTNF-α tumor necrosis factor-alpha
UC ulcerative colitis
ULN upper limit of normal
WBC white blood cell
WHODRUG World Health Organization Drug Dictionar
yCCI
CCI
Property of Takeda: For Nonseriouserio
sa
RR
TETEAEAE
TNFTNF
UCommercial Use Only and Subject to the Applicable Terms of Usevitiesvities
Indexndex
yIndexndexy
ocal leukcal leu
nt eventeven
ery y 8 we8 w
MinimiMinim
on-C
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 19of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
3.4 Corporate Identificat ion
TDC Europe Takeda Development Centre Europe Ltd.
TDC Americas Takeda De velopment Cen ter Ame ricas, Inc.
TDC TDC Europe and/or TDC Americas, as applicable
Takeda TDC Europe and/or TDC Americas, as applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 20of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4.0 INTRODUCTION
4.1 Background
4.1.1 Disease and Curre nt Treatments for Chronic or Recurrent Pouchitis
The surgical treatment of c hoice for pat ients with ulcerat ive co litis (UC) is removal of the colon 
followed by construction of an ileal pouch anal anastomosis (IPAA). Inflammat ion of the “pouch,” 
commo nly called pouchi tis, is the m ost comm on long-term com plicat ion in these pat ients and is 
charac
terizedby watery , som etimes bloody  stool  associ ated wi th urgency, incont inence, 
abdo minal cramps, malaise, and fever. In addit ion to these abnormalit ies, biopsy of th epouch 
shows chronic inflammatory  changes wi th intense infiltrat ion of both acute and ch ronic 
inflammatory  cells. 
Pouchi tis is a poorly  understood condi tion, wi th a reported cumulat ive frequency o f 23% to 46% 
over 10 to 11 years in patients who underwent an ileoanal pouch procedure [1, 2]. The etio logy of 
pouchi tis is likely mult i-factori al. Pouchi tis may be du ein part to exposure of the ileal mucosa of 
the pouch to noxious component sof feces, such as short chain fatty  acids and bile acids, to which 
it may never be com pletely adapted. Altered immunoregulat ion, previously undiagnosed Crohn’s 
disease (CD) affect ing the ileum, and ischemia caused by decreased mucosal blood flow may also
be involved in the etiology of pouchi tis [3]. 
The clinical response of pouchit is to tre atment wi th antibiot ics such as metronidazo le or 
ciprofl oxacin, as well  as probi otics includin gLactobacilli , suggests that fecal stasis, Cdifficile 
infect ion, bacterial overgrowth, or dy sbiosis (altered proporti ons am ong fecal bacteri al 
popul ations) may  
be triggers. Other therapeutic agents tested for the treatment of pouchit iswith 
mixed success include mesalamine, corticosteroids, nutritional agents (short -chain fatty  acids, 
glutamine, or sol uble fiber administered per suppository  or enem a), immuno modifying agents, 
cigarettes and transdermal nicotine, bisthmus -containing agent s, and allop
urino l [3]. Importantly, 
none of these therapies have been shown to be effect ive in clinical trials. Furthermore, due to their 
nonspecific mechanism o f
action, use of som e of these therapi es may place pat ients at ri sk for 
infect ion complicat ions. 
Results fro m 3 clinical trials o f the probiotic agent VSL#3 for the primary and secondary  
prophylaxis of pouchit is have been published [
4-6]and showed efficacy around 85% to 90%. 
However, long -term efficacy  in routine care coul d not be reproduced in another study  [7]. 
While pouchit is usually responds to short -term antibi otic therapy , some pati ents experi ence 
recurrent pouchit is and require chronic ant ibiotic therapy to sustain remissio n or the more drastic 
option of  surgical  remo
val of the p ouch. C hronic or recurrent pouchit is is often managed wit h 
long-term antibiotic administration, with metronidazole and ciproflo xacin being the ant ibiotics 
most often pres cribed [8]. The re are present ly no approved drugs for the treatm ent or prevent ion of 
pouchi tis in the United States or Europe. Thus, a large unmet medical need exists in the 
management of refractory  pouchi tis.
Although many pat ients respond to antibiotic therapy, there i s also evi dence to sug gest that 
aberrant regulat ion of the mucosal immune system might play a part in the pathogenesis of 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 21 of 107Protocol Incorporating Amendment No. 04 14 September 2020
pouchitis arising from an abnormal mucosal imm une response to a dysbiosis of the pouch 
microbiota [9]. For example, pouchitis rarely occurs in patients with familial adenomatous 
polyposis (FAP) who have undergone a colectomy with creation of IPAA [10]. There are known 
genetic risk factors for the development of pouchitis associated with a dysregulation of the 
mucosal immune system [11]. The interleukin-1 receptor antagonist gene allele 2, tumor necrosis 
factor gene allele 2, and NOD2/CARD15 polymorphisms have all been associated with pouchitis 
[12-15] .
Herfarth et al conducted a systematic review of the use of biologics in the treatment of pouchitis 
[16]. Well-controlled clinical studies of tumor necrosis factor-alpha (TNF- α) antagonist therapy in 
the treatment of pouchitis were not available. However, the available data for infliximab suggests 
potential clinical effectiveness in the treatment of anti biotic refractory or fistulizing pouchitis. The 
data for adalimumab are more limited and sufficient long-term outcomes were lacking. There are 
no published data available related to the efficacy of certolizumab, golimumab, natalizumab, or 
vedolizumab in patients with antibiotic refractory pouchitis or fistulizing and/or pouch 
complications [16]. Subjects with pouchitis were excluded from the pivotal phase 3 clinical studies 
for vedolizumab.
4.1.2 Vedo lizumab
Vedolizumab (also called MLN0002) is a humanized immunoglobulin G1 (IgG1) monoclonal 
antibody (mAb) directed against the human lymphocyte integrin α4β7. The α4β7 integrin mediates 
lymphocyte trafficking to gastrointestinal (GI) mucosa and gut-associated lymphoid tissue 
(GALT) through adhesive interaction with mu cosal addressin cell adhesion molecule-1 
(MAdCAM-1), which is expressed on the endothelium of mesenteric lymph nodes and GI mucosa 
[17-20] . Vedolizumab binds the α4β7integrin, antagonizing its adherence to MAdCAM-1 and as 
such, impairs the migration of gut homing lymphocytes into GI mucosa. As a result, vedolizumab 
acts as a gut-s elective immunomodulator [21].
Vedolizumab IV (also known as ENTYVIO; KYNTELES; or MLN0002 IV) has been granted 
marketing approval in several regions, including the United States, European Union, and several 
other countries worldwide. Vedolizumab IV is approved for the treatment of adult patients with 
moderately to sever ely active UC or CD, who have had an inadequate response with, lost response 
to, or were intolerant to either conventional therapy (corticosteroids, immunomodulators) or a 
TNF-α antagonist. The approved dosing regimen is 300 mg vedolizumab IV infused intravenously 
at Weeks 0, 2, and 6, then once every 8 weeks (Q8W) thereafter. 
pharmacokinetics (PK), pharmacodynamics (PD), a nd immunogenicity of vedolizumab in healthy 
subjects and subjects with UC or CD.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen 
ecrocrossisi
h pouchipouch
ment of pment of
antagonntagon
for inflior infl
r fistulifistu
mes wees w
b, golim, golim
fistulizifistuliz
om tm the he
anized imanized 
lymphoympho
(GI) mu(GI) m
wiiththiimmhhumm
on tn the enhe 
α4ββ77intin
gut homgut ho
unomodnomo
known anown
in severin seve
orlldwiddw
eveeverelyre
ntoleranntolera
ntagonistagon
eks 0, 2eks 0, 
operty of Ta
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 22of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4.1.2.1 Nonclinical
No nonclinical studies have been conducted to e valuate vedo lizumab specif ically for chronic 
pouchi tis in UC.
Nonclinical in vitro and in vivo studies have been conducted with vedo lizumab and its murine 
homolo gue, Act -1. Act -1 has demo nstrated clinical and histo morphologic evidence of efficacy in a 
cotton-toptamarin model o f inflammatory  bowel disease (IBD). Extensive nonclinical evaluat ions 
of the cardiovascular, acute, local, subchronic, chronic, immuno logic, and reproductive toxicit y of 
vedo lizumab in pharmaco logically responsive species (New Zealand whiterabbit s and 
cyno molgus m onkeys) have been conducted and support its clinical development. Nonclinical 
studi es also show that vedolizumab does not antagonize α 4β1integrin [21].
4.1.2.2 Huma n Experience
As of 19 November 2016 , approximately  4200 subjects (309 healthy subjects, 1811 subjects with 
UC, 2138 subjects with CD, 3 subjects undergoing al l
o-HSCT, 1 subject with pouchit is, and 2 
subjects wi th melano ma) have r eceived at least 1 dose of vedo lizumab a cross com pleted and 
ongoing company -sponsored intervent ional clinical studies (see Investigator’s Brochure [IB], 
Edition 19). Vedolizumab exposur ehas extended for ≥12months in 1832 subjects, ≥24 months in 
1379 subj ects, ≥36 months in 1169 subjects, ≥48 m onths in 862 subjects, ≥60 months in 
645subjects, ≥72 months in 308 subjects, ≥84 months in 32 subjects, and ≥96 months in 22 
subjects. Based on drug shipment data, the global cumulat ive postmarket ing patient exposure to 
vedo lizumab IV globally is est imated to be approximately 77,382 pa tient-years.
In the 52- week pivotal phase 3 studi es (C13006 and C13007), the most commo n (≥5% and at a 
higher inc idence than placebo) adverse events in subjects administered vedolizumab IV were 
nausea, nasopharyngit is, upper respi ratory  tract infecti on, arthral gia, py rexia, fat igue, headache, 
and cough. Most serious adverse events (SAEs) were related to exacerbat ionsor com plicat ions of 
the underlying UC or CD. For those infect ions that were reported more frequent ly in 
vedo lizumab -treated subjects, the sites of these infections correlate with the known t issue 
distribut ion of MAdCAM -1 binding sites. Anal abscess, abdo minal abscess, and gastroenterit is 
were the most frequently reported serious infect ions. Extraintestinal infect ions (bronchi tis, 
pneumo nia, urinary  tract infect ion, sepsis) occurred at low frequency (<1%). Concomitant use of 
corticosteroi ds and/or convent ional immuno modulators di d not appear to be associated with any  
increased rate of infections based on the compara tive rates of infections in the phase 3 clinical 
studi es am ong subjects. One death occurred in a vedolizumab -treated subject during Study  
C13006 and 5 deaths occurred during Study  C13007, including 1 death in a placebo -treated 
subject. Results from the cli nical  program  to date do not suggest an increased risk for malignancy 
with vedolizumab treatment. No cases of progressive mult ifocal leukoencepha lopathy  (PML) 
were reported in these studies.
Overall, 4% of subjects treated with vedo lizumab IV and 3% of subjects treated with placebo 
experienced a treatment -emergent adverse event (TEAE )defined by the invest igator as an 
infusio n-related reacti on (IRR ). The m ost frequently  observed IRR events in the subjects treated 
with vedolizumab (by  preferred term  and repo rted more than twice) were nausea, headache, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 23of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
pruri tus, di zziness, fat igue, IRR, pyrexia, urticaria, and vo miting. The majorit y of IRRs were mild 
or moderate in intensit y, and few resulted in discont inuat ion of study  treatm ent. Observed IRRs 
generally reso lved with no or minimal intervent ion following the infusio n. 
Overall, vedo lizumab was well tolerated in clinical studies. For addit ional safet y related 
inform ation from the clinical trials experience, see the current edition o f the IB.
4.2 Rationale for the Pr oposed Study
There are present ly no approved drugs for the treatment or prevention o f pouchi tis in the United 
States or Europe. Thus, a large unm et medical need exists in the management of pouchit is.
While pouchit is usually responds to short -term antibi otic therapy , approximately  5%to 19% of 
patients wi th acute pouchit is develop refractory or rapidly relapsing forms of the disease [22, 23] . 
Chronic or recurrent pouchitis is often managed with long -term antibiotic administration, with 
metronidazo le and c iprofl oxacin being the ant ibiotics most often prescribed [
8]. The disease 
course of ant ibiotic-responsive pouchit is may evo lve into antibiot ic-dependent pouchit is and then 
antibiotic-refractory  pouchi tis. In cases where chronic or recurrent pouchitis does not respond to 
therapy , this may  necessi tate the drasti c opti on of  surgi cal removal of the pouch.
Although many pat ients respond to antibiot ic therapy, there is also evidence to suggest that 
aberrant regulat ion of the mucosal immune system might play a part in the pathogenesis of 
pouchi tis arising from  an abno rmal mucosal immune response to a dysbiosis of the pouch 
microbiota [
9].
The humanized mAb vedo lizumab is effect ive for induct ion and m aintenance therapy  of UC and 
CD [24-28] . Vedoli zumab abrogates the interaction of α 4β7integrin on memory T and B cells wit h 
MAdCAM -1 expressed on the vascular endothelium in the gut [
19, 20]. MAdCAM -1 levels are 
elevated in IBD [19]. This mechanism o f action suggests that vedolizumab may be effect ive in t he 
treatm ent of other chronic inflammatory  diseases of the GI tract, such as chronic or recurrent 
pouchi tis. It is hypothesized that vedolizumab IV will effect ively and safely  achieve clinically 
relevant remissio n in subjects with chronic or recurrent pouc
hitis. Thi s study  will establish 
whether vedo lizumab IV may be an effect ive therapy  for chroni c or recurrent pouchit is. 
4.3 Benefit -Risk Assessment
The proposed study  (Vedolizumab -4004) is designed to evaluate the efficacy  and safet y of 
vedo lizumab IV in the treatm ent of adul t subjects wi th chroni c or recurrent pouchit is. Current ly, 
no drugs have been approved in the United States or Europe for the treatment or prevent ion of 
pouchi tis, indicat ing that a high unmet medical need exists for this patient populat ion
.
Inhibit ion of the interaction of the α 4β7integrin on memory T and B cells wit h MAdCAM -1 
expressed on the vascular endothelium in the gut may be effect ive in the treatment of chronic 
inflammatory  diseases of the GI tract, such as chronic or recurrent pouchitis. All subjects will 
receive conco mitant antibiot ic treatment with ciproflo xacin 500 mg twi ce daily  through Week 4. 
Addit ional courses of ant ibiotics will be allowed, as needed, for flares after Week 14.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 24of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
The dosing and administration regimen of vedo lizumab are consistent wi th the approved 
vedo lizumab IV label. The proposed protocol will include safet y measures similar to those 
conducted in the vedo lizumab IV UC and CD clinical programs, including sufficient safet y 
measures, evaluat ions, and discont inuation crit eria to assure safet y in t he individual subjects in the 
planned study .
Overall, vedo lizumab IV has been well tolerated in clinical studies and the benefit -risk profile is 
positive.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 25 of 107Protocol Incorporating Amendment No. 04 14 September 2020
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective
The primary objective is to compare the efficacy of vedolizumab IV to placebo in terms of the 
percentage of subjects with chronic or recurrent pouchitis achieving clinically relevant remission 
5.1.2 Secondary Objectives
The secondary objectives are to asse ss the efficacy of vedolizumab IV by:
!Percentage of subjects achieving mPDAI <5 and a reduction of overall score by ≥2 points from 
Baseline mPDAI.
!Percentage of subjects achieving PDAI <7 and a reduction of overall score by ≥3 points from 
Baseline PDAI. 
!Time to remission (defined as a PDAI score <7 and a decrease in PDAI score of ≥3 points from 
Baseline).
!Percentage of subjects achieving a partial response (defined as reduction mPDAI score by ≥2 
points from Baseline). 
!Change in PDAI endoscopic subscore. 
!Change in PDAI histologic subscore. 
!Change in total PDAI.
!Change in Inflammatory Bowel Disease Questionnaire (IBDQ), and Cleveland Global Quality 
of Life (CGQL, Fazio Score, 3 items). 
5.1.3 Exploratory Objectives
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses of theof th
ant nt remire
erall scorall sc
of overof ove
a decreadecre
sponse (ponse
e. 
ore. ore. 
Bowel Bowe
o Score, Score
y ObjecObje
operty of Takeda: For N
Vedolizumab IV
Study No. Vedolizumab-4004 Page 26 of 107Protocol Incorporating Amendment No. 04 14 September 2020
5.1.4 Safety Objective
The safety objective is to assess the safety of vedolizumab IV in chronic or recurrent pouchitis.
5.2 Endpoints
5.2.1 Primary Endpoint 
The primary efficacy endpoint is the percentage of subjects with chroni c or recurrent pouchitis 
achieving clinically relevant remission after 14 weeks of treatment. Clinically relevant remission 
is defined as an mPDAI score <5 and a reduction of overall score by ≥2 points from Baseline.
5.2.2 Secondary Endpoints
Secondary efficacy endpoints are:
!Percentage of subjects achieving an mPDAI score <5 and a reduction of overall score by ≥2 
points from Baseline after 34 weeks of treatment (last dosing at Week 30).
!Percentage of subjects achieving PDAI score <7 and a reduction of overall score by ≥3 points 
from Baseline PDAI score after 14 weeks of treatment and after 34 weeks of treatment (last 
dosing at Week 30).
!Time to remission (defined as a PDAI score <7 and a decrease in PDAI score of ≥3 points from 
Baseline).
!Percentage of subjects achieving a partial response (defined as reduction in mPDAI score by 
≥2 points from Baseline) after 14 and after 34 weeks of treatment (last dosing at Week 30).
!Change in PDAI endoscopic subscore at Weeks 14 and 34 compared to Baseline.
!Change in PDAI histologic subscore at Weeks 14 and 34 compared to Baseline.
!Change in total PDAI score at Weeks 14 and 34 compared to Baseline.
!Change in IBDQ, and CGQL (Fazio Score, 3 items) at Weeks 14, 22, and 34 compared to 
Baseline.
5.2.3 Exploratory Endpoints
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useent poucnt pou
elevant elevant
ts froms from
a reductireduc
sising at ng a
d a redua red
ment ment an
e <7 an<7 a
partial partia
4 and a4 and 
c subscosubs
ogic subogic su
DAI scorAI sco
DQ, and Q, an
xploratoplora
operty of Taked
Vedolizumab IV
Study No. Vedolizumab-4004 Page 27 of 107Protocol Incorporating Amendment No. 04 14 September 2020
5.2.4 Safety Endpoints
Safety will be assessed by adverse events (AEs), adverse events of sp ecial interest (AESIs), SAEs, 
vital signs, and results of standard laboratory tests (clinical chemistry, hematology, coagulation, 
and urinalysis).CCI
Property of Takeda: For Non-Commercial Use Only and Subjrse evenrse ev
(clinica(clinicbject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 28of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
6.0 STUDY DE SIGN AND DESCRIP TION
6.1 Study Design
This is a phase 4, randomized, double -blind, placeb o-controlled, mult icenter study  to eval uate the 
efficacy  and safet y of vedo lizumab IV 300 mg over a 34 -week treatment period (with the last dose 
at Week 30) i n subject s with a proctocolec tomy and IPAA for UC who have developed chronic or 
recurrent pouchit is. 
Approximately  110 adul t subjects wi th chronic or recurrent p ouch itis will be rando mized to this 
study . Subjects m ust have develope d chronic or recurrent pouchi tis, defined as a modified 
Pouchi tis Disease Act ivity Index (m PDAI) score ≥5 assessed as the average fro m 3 days 
immediately  prior to the Baseline endoscopy  and a minimum endoscopic subscore of 2 (outside 
the stapl e or suture l ine) with either (a) ≥3 recurrent episodes wi thin 1 year prior to the Screening 
visit, each treated with ≥2 weeks of ant ibiotic or other prescript ion therapy , or (b) requi ring 
maintenance ant ibiotic therapy taken continuously for ≥4 weeks immediately prior to the B aseline 
Endoscopy  Visit.
After the Screening Per iod of up to 28 days, subjects will be rando mized at Day 1 in a 1:1 ratio to 
either vedo lizumab IV or placebo treatment. Subjects will receive their assigned infusio n 
(vedo lizumab or placebo) at Day 1, Weeks 2, 6, 14, 22, and 30 (final dose). All subjects will 
receive conco mitant antibiot ic treatment with ciproflo xacin 500 mg twi ce daily  through Week 4. 
Addit ional courses of ant ibiotics will be allowed, as needed, for flares after Week 14. Final 
efficacy asses smen ts will be measu red 4 weeks after the last s tudy dose (Week 34). Addit ional 
safet y follow-ups will  occur 18 weeks after the last study  dose (Week 48) and subjects will be 
requi red to participate in a long -term follow-up (LTFU) safet y sur vey by telephon e, 26 weeks after 
the last dose of study  drug (W eek 56).
A schemat ic of the study  design is included as Figure 6.a. A schedule o f assessments is listed in 
Appendix A.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 29of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Figure 6.a Schematic of Study Design
6.2 Justification for Study Design, Dose, and Endpoints
In 1310 patients who had an IPAA for chronic UC, 559 patients had at least 1 episode of pouchit is. 
Approximate ly 70% of those pati ents who had at least 1 attack of pou chitis had a second episode 
[29]. There are currently no approved drugs for the treatment of chronic or recurren t pouchi tis. 
Chronic pouchi tis is often managed with long-term antibiot ic administration; however, long -term 
antibiotic use can lead to antibiot ic resistance. The treatment of antibiot ic refractory  pouchi tis is 
also often challenging. While a prol onged cou rseof co mbined ant ibiotic agents is often used,
maintenance of remissio n in this group of patients after induct ion treatment with combined 
antibiotics remains challenging and represents an unmet need [
30]. Existing data suggests 
infliximab may be clinically effect ive for antibiotic
-refractory  pouchi tis, but well- controlled 
studi es are not present ly available for any TNF -α antagoni st therapi es [16]. The m echanism  of 
action of  vedolizumab suggests that it may be effective in the treatment of chronic inflammatory 
diseases o f the GI tract, such as pouchit is. Based on thes e considerat ions it is proposed that 
vedo lizumab IV may be efficacious in achieving disease remissio ninthe study  popul ation 
defined. 
Since there are no approved drugs for chronic or recurrent pouc hitis, th e placebo -controlled desig n 
was selected. The do se and administration regimen selected for the vedolizumab IV treatment 
group i s consistent with the approved label for UC [
31, 32] .
6.3 Premature Termination or Suspension of Study or Study Site
6.3.1 Criteria for P remature Termin ation or Suspension of the S tudy
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  terminat ion (ET) of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 30of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
New informat ion or other evaluat ion re garding the saf ety or efficacy  of the study drug that 
indicates a change in the known risk/benefit profile for vedo lizumab, such that the risk /benefi t 
is no longer acceptable for subjects participat ing in the study.
Significant vio lation of Good Clini cal P ractice (GCP) t hat compromises the abilit y to achieve 
the primary  study  objectives or compromises subject safet y.
At the futilit y analysis, if the probabilit y of success does not meet the pre -determined fut ility 
thresho ld and the study is sto pped for futility at this poi nt.
6.3.2 Criteria for Premature T ermination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contrac tual agre ement , is unable to ensure 
adequate performance of the study , or as otherwise permitted by  the contractual  agreem ent.
6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)
In the event that the spons or, an in stitutional review b oard (IRB)/independent ethic s committee 
(IEC) or regulatory  authori ty elects to terminate or suspend the study  or the parti cipat ion of an 
study  site, a study -specific procedure for ET or suspensio n will be provided by the spons or; the 
proced ure will be fo llowed by applicable study  sites during the course of terminat ion or study  
suspension.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 31of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria, including test results, need to be confirmed prior to randomizat ionand first dose.
7.1 Inclusion Cri teria
Subject eligibilit y isdetermined according to the following criteria prior to entry  into the study : 
1.In the opinion o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2. T he subjec t or,when applicabl e, the subject’s legally acc eptable representative signs and dates 
a wri tten, informed consent form and any  required privacy  authori zation prior to the init iation 
of any study  procedures.
3.The subject is male or female and aged 18 to 80 years , inclusive.
4.The subject has a history  of IPAA for UC com pleted at l east 1 year prior to the Day 1 
(Rando mizat ion) Visit.
5.The subject has pouchitis that is chronic or recurrent, defined by an mPDAI score ≥5 assessed 
as the average fro m 3 day simmediat ely p rior to the Bas eline endoscopy  and a minimu m 
endoscopi c subscore of 2 (outside the staple or suture line) with either (a) ≥3 recurrent episodes 
within 1 year pri or to the Screening Period treated with ≥2 weeks of ant ibiotic or other 
prescri ption therapy , or (b) requiring maintenance ant ibiotic ther apy taken continuously for ≥4 
weeks immediately prior to the Baseline Endoscopy Visit
6.The subject agrees to take ciproflo xacin (500 mg twice daily) on Day 1 and through Week 4, 
regardl ess of the prev ious trea tmentand to stop an y previous ant ibiotic therap y on Day 1 of the 
study . (Addi tional courses of ant ibiotics will be allowed, as needed, for flares after Week 14.)
7.A male subject who is nonsterilized* and sexually active wit h a female partner of ch ildbearin g 
potential* agrees to use a barrier method of c ontraception (eg, condom with spermicide)* fro m 
signing of informed consent throughout the duration of the study  and for 18 weeks after last 
dose. The female partner of a male subject should also be advised t o use a highly effec tive 
method of contraception *.
8.A female subject of childbearing potential* who is sexually act ive with a nonsterilized* male 
partner agrees to use a highly effective method of contraception* fro m signing o f informed 
consent thr oughout t he du ration of the s tudy and for 18 weeks after last dose. 
*Definit ions and highly  effect ive methods of contraception are defined in 
Secti on9.1.21 Contraception and Pregnancy Avo idance Procedure and 
reporting respo nsibilit ies are defined in Sect ion 9.1.22 Pregnancy.
7.2 Exclusion Criteria
The exclusio n criteria are divided into 3 categories: GI exclusio n criteria, infect ious di sease 
exclusio n criteria, and gene ral exclu sion criteria. Subje cts m eeting any o f the following criteria 
will not qualify for entry  into the study : 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 32of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
7.2.1 Gastrointestinal Exclusion Criteria
1.The subject has CD or CD of the pouch. Subjects will be excluded if the investigator suspects, 
on the bas is of the screening endoscopy , that the pattern of inflam mation may be due to CD.
2.The subject has irritable pouch syndro me (IPS).
3.The subject has iso lated or predominant cuffit is.
4.The subject has mechanical co mplications of the pouch (eg, pouch stricture o r pouch f istula).
5.The subject currently requires or has a planned surgi cal intervent ion for UC during the study .
6.The subject has diverting stoma.
7.2.2 Infectious Disease Exclusion Criteria
1.The subject has evidence of an act ive infect ion (eg, sepsis, cytomegalo virus, or listeriosis) 
during Screening.
2.The subject has a ctive or latent tuberculosis (TB), regardless of treatment history, as 
evidenced by any  of the f ollowing:
a)A diagnostic TB t est performed within 30 days of Screening or during the Screening Period 
that is posi tive, as defined by:
i.A posi tive QuantiFERON test or 2 successive indeterminate QuantiFERON tests OR
ii.A tuberculin ski n test reaction ≥10 mm (≥5 mm in subjects receiving the equivalent of 
>15 m g/day  prednisone) OR
b)Chest X -ray within 3 m onths pri or to Day  1 that is suspicious for pulmo nary TB, and a 
positive or 2 successive indeterminate QuantiFERON test within 30 days pri or to 
Screening or during the Screening Period.
Note: if the subject has a negat ive diagnostic TB test documented in the previous 3 months, 
screening testing does not need to be repeated provided subject has no risk factors for 
exposure.
3.The subject has ch ronic hepat itis B virus (HBV) infect ion* or chronic hepat itis C virus 
(HCV) infect ion** or a known history  of human immunodeficiency  virus (HIV) infect ion 
(or is found to be seroposit ive at Screening) or subject is immunodeficient (eg, due to organ 
transpl antati on, history  of comm on variable immunodeficiency, etc). 
* Subj ects who are posit ive for hepatit is B virus surface ant igen (HBsAg) will be excluded. 
For subjects who are negative for HBsAg but are posit ive for either surface ant ibodies 
and/or core ant ibodies, HBV DNA polymerase chain reaction will be performed and if any 
test result meets or exceeds detection sensit ivity, the subject will  be excluded.
** If subject is HCV ant ibody  posi tive, then a viral load test will be performed. If the viral 
load te st is positive ,then the subject will be excluded.
4.The subject has evidence o f active infect ion with C difficile during Screening (to be confirmed 
by laboratory  test). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 33of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
7.2.3 General Exclusion Criteria
1.The subject has any  prior exposure to vedolizumab, natalizum ab, efalizumab, rituximab, 
etrolizumab, or anti -MAdCAM -1 therapy .
2.The subject has a history  of hypersensi tivity or allergi es to vedolizumab or its components.
3.The subject has allergies to and/or contraindicat ions forciproflo xacin, a history  of tendon 
disorders related to quinolone administration and/or glucose -6-phosphate dehydrogenase 
(G6PD) deficiency. Further conditions requiring precautions for use of cipro floxacin have to 
be considered based on local prescribing informat ion. 
4.The subject is taking, ha staken, or i s requi red to take any  excluded m edicati ons (as listed in 
Secti on
 22).
5.The subject has received any invest igational or approved bio logic or bi osimilar agent within 
60days prior to Randomizat ion
6.Thesubject has received an invest igational nonbio logic therapy  within 30 days prior to 
Randomization.
7.The subject has received an approved nonbio logic therapy  (including 5 -aminosalicylate 
[5-ASA], corticosteroid, azathioprine, 6 -mercaptopurine [6 -MP], etc.) in an invest igational 
protocol  within 30 days prior to Randomization.
8.The subject has received any live vaccinat ions wit hin 30 days prior to randomizat ion.
9.The subject has a posit ive PML subject ive symptom checklist at Screening.
10.[Previous criterion #10 in corporated into criterion #3 in amendment number 3 ].
11.The subject has had a kidney, heart, or lung transplant.
12.[Previous criterion #12 deleted in amendment number 3 ].
13.The subject has a history  of malignancy , except for the following: adequately -treated 
nonm
etastati c basal cell skin cancer; squamous cell skin cancer that has been adequately 
treated and that has not recurred for at least 1 y ear pri or to the Screening visit ; and history  of 
cervical carcino ma in situ that has been adequately treated and that has not recurred for at least 
3years prior to Screening. Subjects with a remote history  of malignancy  (eg,>10 y ears since 
completion of curative therapy  without recurrence) will be considered based on the nature of 
the malignancy  and the therapy  received an dmust be discussed wit h the sponsor on a 
case-by-case basis prior to enrollment.
14.The subject has a history  of any major neurol ogical disorders, including stroke, mult iple 
sclerosi s, brain tum or, demyelinat ing, or neurodegenerat ive disease.
15.The subject has condi tions which, in the opinio n of the investigator, may interfere with the 
subject’s abilit y to comply with the study  procedures.
16.The subject has any  unstable or uncontrolled cardiovascular, pulmo nary, hepatic, renal, GI, 
genitourinary , hematol ogical, coagulation, immunological, endocrine/metabo lic, neuro logic, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 34of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
or other medical disorder that, in the opinio n of the invest igator, would confound the study 
resul ts or com promise subject safet y.
17.The subject has any  of the f ollowing laboratory  abnorm alities dur ing the Screening Period:
i. Hem oglobin level  <8 g/dL.
ii. White blood cell (WBC) count <3 × 109/L.
iii. Lymphocy te count <0.5 × 109/L.
iv. Platelet coun t <100 × 109/L or >1200 × 109/L.
v. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 
× the upper limi tof normal (ULN).
vi. Alkaline phosphatase >3 × ULN.
vii. Serum  creatinine >2 × ULN.
18.If female, the subject is pregnant or lactating or intending to become pregnant or nurse before, 
during, or within 18 weeks after the last dose of study  drug; or intending to dona te ova during 
such time period.
19.If male, the subject intends to donate sperm or father a child during the course of this study or 
for 18weeks after the last dose of study  drug.
20.The subject is an immediate family member, study site emplo yee, or i s in a depe ndent 
relationship with a study  site em ployee who i s involved in conduct of this study  (eg, spouse, 
parent, child, sibling) or may consent under duress. 
21.The subject has a history  of drug abuse (defined as any  illici t drug use) or a hi story  of alcohol  
abuse within 1 y ear pri or to Screening.
22.[Previous criterion #22 incorporated into criterion #3 in amendment number 3 ].
7.3 Excluded Medications
The fo llowing medicat ions are excluded fro m use during the study unt il Week 34 unless specified 
otherwi se:
1.Any treatmen tfor pouchitis other than those listed below in Sect ion 7.3.1 (either approved or 
investigat ional). 
2.Antibiotic therapy for pouchit is from Week 4 through Week 14 of  the study . (Ant ibiotics will 
be allowed after Week 14, as nee ded, f or flares.)
3.Tizanidine, methotrexate, and zolpidem fro m Randomizat ion to Week 4 (contraindicat ion to 
ciprofl oxacin)
–Several drugs might interfere with cipro floxacin when administered concomitantly. Use 
with caut ion or monitoring (especially drugs met abolized by CYP1A2) may be required 
(as detailed in local prescribing informat ion). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 35of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4.Oral corti costeroi ds for pouchi tis, except as described in Sect ion 7.3.1.1 .
5.Within 30 days prior to Randomization and througho ut study  until Week 34, any  of the 
following for the treatment of pouchit is:
–Nonbio logic therapi
es (eg, cycl osporine, thali domide) other than those specifically  listed 
in Section 7.3.1 .
–An invest igational nonbio logic therapy .
–An approved nonbio logic therapy  in an invest igational protocol .
6.NSAIDS (if used cont inuously for ≥2 weeks) within 30 days prior to Rando mizat ion (Day  1) 
and throughout the study  until  Week 34
–Note: occasional use of NSAIDs and acetaminophen for headache, arthritis, myalgia, 
menstrual cramps etc. and daily use of low do se (≤100 mg acet ylsalicylic acid for 
cardi ovascular prophylaxis are permitted) .
7.Any invest igational or approved bio logic or bi osimilar agent wi thin 60 days prior to 
Randomization (Day 1) and throughout the study  until Week 34. 
8.All live vaccines wit hin 30 days prior to randomization, throughout the study treatment period 
and for at least 6 months after the last dose of study  drug.
9.Either approved or invest igational biologic agents for the treatment of non -IBD condi tions, 
other than localized inject ions (eg, intra-ocular injecti ons for wet m acular degenerat ion).
10.Rectal  products (enemas and suppositories including 5- ASA and corticosteroids) within 15 
days pri or to Rando mizat ion (Day  1) and throughout the study  until  Week 34. 
Subjects m ust be instructed not to take any  medicati ons including over -the-counter products, 
without fi rst consul ting wi th the investi gator. 
7.3.1 Permitted Medications and Treatments
The fo llowing m edicat ions for pouchit is are permit ted during the study :
1.Ciprofl oxacin (500 m g twi ce daily for 4 weeks, starting at Rando mizat ion) is mandatory  
therapy  in this study. If subjects are receiving other ant ibiotics at Randomization, they will be 
switched to ci profl oxacin and continue on this for the first 4 weeks of the study . 
2.Addit ional antibiot ics wil l be allowed, as needed, for flares after Week 14.
3.Oral 5-ASA if taken at a stable dose for at least 2 weeks prior to randomizat ionand throughout 
the study  until Week 34 .
4.Anti-diarrheals for control of chronic diarrhea, with stable dose for at least 2 wee ks prior to 
Randomization and throughout the study  until  Week 34.
5.Antibiotic therapy for pouchit is if taken before Screening should be kept at a stable dose for 2 
weeks prior to Rando mizat ion.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 36of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
6.Oral corti costeroi d therapy  for pouchi tis if taken at a stabl e dose for at l east 4 weeks prior to 
Randomization and wit h mandatory  tapering after Week 4 (Visit 4) of the study  as described 
in Section 7.3.1.1 .
7.Probi otics (eg, Saccharomyces boulardii) and/or immuno modulators (azathioprine, 6 -MP), if 
taken at a stable dose for at least 8 weeks prior to Randomizati on and throughout the study  
until Week 34.
7.3.1.1 Oral Corticosteroid Dosing and Tapering
The m aximum  dose of oral  corti costeroi ds for the treatm ent of pouchit is that may be 
co-administered with vedo lizumab IV is 20 mg/day predniso ne or 9 mg/day budesonide or 5 
mg/day  becl omethasone dipropionate (or equivalent) as long as they  have been used at a stable 
dose for at l east 4 weeks prior to Randomizat ion.
It is requi red that subj ects receiving oral corticosteroids begin a tapering regimen by Week 4 
(Visit4) of  the study . Tapering should be finished by  Week 8, if possible.
7.4 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.23 .
1.Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires ET 
because cont inued participat ion imposes an unacceptable risk to the subject’s health or the 
subject is unwilling to continue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormali ties.
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 9.1.17 ), if the following circumstances occur at any 
time during study  drug treatm ent:
–ALT or AST >8 × ULN, or
–ALT or AST >5 × ULN and persists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or 
international normalized rati o (INR) >1.5, or
–ALT or AST >3 × ULN with appearance of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
Leukopenia or lymphopenia: WBC and lymphocy te counts will be mo nitored for all 
subjects. Azathioprine, 6- MP, if applicable, should be discontinued and the dose of 
vedo lizumab held for an abso lute lymphocy te count <0.5×109/L at any po int in the study . 
The abso lute lymphocy te count must be repeated at appropriate intervals as d e
termined by 
the invest igator. The next dose of vedo lizumab can be administered only if the absolute 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 37of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
lymphocy te count i s ≥0.5×109/L. If the abso lute lymphocy te count rem ains <0.5×109/L, 
study  drug shoul d be discont inued and the subject withdrawn from the s tudy.
2.Significant protocol  deviat ion. The discovery  post-rando mizat ionthat the subject failed to 
meet protocol entry  criteria or di d not adhere to protocol requirements, andcontinued 
participat ion poses an unacceptable risk to the subject’s healt h.
3.Lost t
ofollow-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
docum ents.
4.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the study . The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  unde r
lying reason should be recorded (ie, withdrawal due to an 
AE should not be recorded in the voluntary withdraw alcategory . Similarly , lack of efficacy  
shoul d not be recorded in the voluntary withdrawal category).
5.Study  terminat ion. The sponsor, IRB, IEC, o rregulatory  agency  terminates the study .
6. Pregnancy. The subject is found to be pregnant. 
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.22 .
7.Lack of efficacy. The invest igator has determined that the subject is not benefit ing fro m 
investigat ional treatm ent; and, continued participatio n would pose an unacceptable risk to the 
subject. 
8.Other.
Note: The specific reasons should be re corded in the “specify” field of the eCRF.
7.5 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subject meets the study termination criteria describ edin Section 7.4. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion mus
tbe recorded by  
the invest igator. In addit ion, efforts should be made to perform all procedures scheduled for the ET 
Visit and post -treatm ent follow-up visi t and safet y phone call (18 and 26 weeks post -treatm ent). 
Discont inued or wi thdrawn subjects will not be replaced. Refer to Section 9.3.9 for appropri ate 
Post-Study Care procedures.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 38of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT
This sect ion contains informat ion regarding all medicat ion and m aterials pr ovided di rectly by the 
sponsor, and/or sourced by  other m eans, that are requi red by the study  protocol , including 
important sections describing the management of clinical trial material.
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and L
abeling 
8.1.1.1 Vedolizumab IV and Placebo
The study  sites will be supplied by the sponsor with the following medicat ion in an open -label 
manner: vedo lizumab IV 300 mg/vial, for single use, in 20 mL vials. The study drug will be 
provi ded in a gl ass vial  as a ly op
hilized so lid for reconstitution using 4.8 mL of sterile water for 
inject ion and further dilut ion (5.0 mL) in 250 mL of sterile 0.9% sodium chloride. Each vial will be 
packaged in an appropriately labeled single vial carton. 
The pl acebo infusio n will be 250 mL o f commercially  available sterile 0.9% sodium chloride 
provi ded by the clinical study  center. For both active vedolizumab and placebo infusio ns, the 
unblinded invest igational pharmacist or designee will mask the IV bags after preparation in order 
to maintain the study  blind.
Addit ional reference informat ion and administration instructions can be found in the pharmacy 
manual.
8.1.1.2 Companion Medication
Treatment with cipro floxacin is required per protocol fro m Day 1 until Week 4 (Vi sit4). 
Ciprofl oxacin 500 mgtwice daily  must be prescribed by  the invest igator as per the local label. 
Ciprofl oxacin will  not be provi ded by  the sponsor but will be reimbursed.
8.1.2 Storage
Study  drug must be kept in an appropriate, limited -access, secure place unt il it is used or retu rned 
to the sponsor or designee for destruction. Study  drug must be stored under the conditions 
specified on the label, and remain in the original container unt il dispensed. 
Vedolizumab IV must be stored at 2ºC to 8ºC (36ºF to 46ºF). A daily temperature l ogof the drug 
storage area must be maintained.
8.1.3 Dose and Regimen
The study drug regimen for both rando mized groups is provided in Table 8.a. The vedo lizumab IV
or placebo/sodi um chlorideinfusio n will  be administere dintravenously over 30 minutes. 
Instructi ons for reconst itution and blinded administration will be provided in the pharmacy 
manual. Subjects should be observed for 2 hours following the first 2 infusions, at a minimum, and 
1hour after each subsequent inf usion.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 39of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
All subjects will receive the ant ibiotic ciproflo xacin fro m Day 1 through Week 4 (Vi sit4).
Table 8.a Dose and Regimen
Treatment Group Dose Treatment Description
1 300 mg vedolizumab IV IV infusion with vedolizumab at Weeks 0, 2, 6, 14, 22, 30
2 0.9% sodium chloride 
(250 mL)IV infusion with placebo at Weeks 0, 2, 6, 14, 22, 30
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study  subje ct, at a dose above that which is assigned to that individual subject according to the 
study  protocol .
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will in addit ion be documented on AE CRF(s) according to Section 10.0, 
Pretreatment Events and Adverse Events.
SAEs associated with overdose should be reported according to the procedure outlined in 
Secti on10.2.2 , Collect ion and Reporting of SAEs.
In the event of drug ove rdose, the subject should be treated symptomat ically.
8.2 Study Drug Assignment and Dispensing Procedures
The invest igator or the invest igator’s designee will access the interactive web response system 
(IWRS) at Screening to obtain the study -specific subject i dentificat ion number (subject number). 
The invest igator or the invest igator’s designee will utilize the IWRS to randomize the subject into 
the study . During thi s contact, the invest igator or designee will provide the necessary 
subject -ident ifying informat i
on, including the subject number assigned at Screening. At 
drug-dispensing visits, the invest igator or designee will again contact the IWRS to register the 
visits. At Day 1, Weeks 2, 6, 14, 22, and 30 for all subjects in both treatment groups, the IWRS wil l
provi de em ail notificat ion to the unblinded site pharmacist/nurse. If the subject is rando mized to 
vedo lizumab IV, a medicat ion ident ification number (Med ID) will be assigned by IWRS and 
provi ded to the unblinded site pharmacist/nurse by email notificatio n. If the subject was 
rando mized to receive placebo, the IWRS will provide email notificat ion to the unblinded site 
pharmacist/nurse, but no Med ID will be assigned. To maintain the blind the IWRS will ensure the 
investigator or designee is unaware if a Med ID has been assigned or not. If sponsor -supplied drug 
(active vials) is lost or damaged, the site can request a replacement from IWRS by the unblinded 
site pharmacist/nurse. Refer to IWRS manual provided separately.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 40of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
8.3 Randomization Code Creation and Stor age 
Randomization personnel o f the sponsor or designee will generate the randomization schedule. All 
rando mizat ion informat ion will  be stored in a secured area, accessible only  by authori zed 
personnel. Subjects will be rando mized in a 1:1 ratio to either vedolizumab or pl acebo treatm ent 
using an IWRS. Rando mizat ion will be stratified to achieve equal distribut ionof patients using 
maintenance ant ibiotic therapy at a stable dose for at least 4 weeks prior to randomization and 
those having had at least 3 epi sodes of pouchit is despite treatment (with pulse ant ibiotics or other 
prescri ption therapy ) during the 1 year prior to baseline endoscopy . 
8.4 Drug Blind Maintenance 
The study  drug blind will be maintained using the IWRS. All subjects and study personnel exc ept 
for those di rectly involved with study  drug preparati on will be blinded to study  drug assignment 
for the ent ire study. In order to maintain the blind, unblinded individuals preparing study drug will 
cover the product in a blinding bag prior to dispensi ng. All  unblinded dosing informat ion must be 
maintained in a secured area, accessible only by  unblinded personnel, and separate from blinded 
inform ation.
8.5 Unblinding Procedure
The invest igational drug blind shall not be broken by the investigator unless inf o
rmation 
concerning the investigational drug is necessary  for the m edical treatment of the subject. In the 
event of a medical emergency , if possible, the m edical m onitor shoul d be contacted before the 
investigat ional drug blind is broken to discuss the nee dfor unblinding.
The invest igator can perform emergency unblinding using the IWRS, if medically necessary. In all 
scenarios, the sponsor must be notified as soon as possible if the invest igational drug blind is 
broken. The date, time, and reason the blin d is broken must be recorded in the source documents 
and the same information (except the time) must be recorded on the eCRF.
If any site personnel (wit h the except ion of the dispensing pharmacist or unblinded site pharmacy 
personnel/nurse) are unblinded, study drug must be stopped immediately ,and the subject must be 
withdrawn from  the study . 
8.6 Accountability and Destruction of Sponsor
-Supplied Drugs
The invest igator and invest igator’s designated site pharmacy must ensure that the 
sponsor -supplied drug is us edin accordance wit h the protocol and is dispensed only to subjects 
enrolled in the study . To docum ent appropri ate use of sponsor -supplied drug (vedo lizumab IV) ,
the invest igator pharmacy must maintain records of all sponsor -supplied drug delivery to the site, 
site inventory , dispensation and use by  each subject, and return to the sponsor or designee.
Upon recei pt of sponsor -supplied drug, the designated site pharmacy must verify the contents of 
the shipments against the packing list. The verifier should e nsure that the quant ity is correct, and 
the medicat ion is in good condit ion. If quantit y and condi tions are acceptable, designated site 
pharmacy personnel should acknowledge the receipt of the shipment by signing bottom half o f the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 41of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
packing list and by reco rding in IWRS. If there are any discrepancies between the packing list 
versus the actual product received, Takeda must be contacted to resolve the issue. The packing list 
shoul d be filed in the invest igator’s essent ial document file.
The invest igator’s des ignated site pharmacy must maintain 100% accountabilit y for all 
sponsor -supplied drugs received and dispensed during his or her ent ire parti cipat ion in the study. 
Proper drug accountabilit y includes, but is not limited to:
Moni toring expirat ion dates (moni tored vi a IWRS).
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the drug accoun tabilit y log is completed for the Medicat ion ID used to prepare 
each dose.
Verifying that all containers used are documented accurately onthe log.
Verifying that required fields are co mpleted accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IWRS will include all required informat ion as a separate entry  for each subject to whom 
sponsor -supplied drug is dispensed.
The invest igator’s designated site pharmacy must record the current inventory of all 
sponsor -supplied drugs (vedolizumab IV) on a sponsor -approved drug accountabilit y log. The 
following informat ion will berecorded at a minimum: protocol number and tit le, name of 
investigator, site ident ifier and number, descript ion of sponsor -supplied drugs, expiry date and 
amount dispensed, and amount returned to the pharmacy  (if applicable) including initials, seal, or
signature of the person dispensing the drug. The log should include all required informat ion as a 
separate entry for each subject (by subject identifier) to whom sponsor -supplied drug is dispensed. 
The invest igator’s designated site pharmacy staff must c omplete an individual subject 
accountabilit y log to docum ent if infusio n was complete or if inco mplete and study  drug was 
returned to the pharmacy, including the date and amount returned to the pharmacy, including the 
initials, seal, or signature of the pe rson administering the infusio n. Only unblinded designated site 
pharmacy personnel and unblinded clinical research associates (CRAs) can perform drug 
accountabilit y and only unblinded designated site pharmacy staff and unblinded clinical CRAs can 
process d rug returns in order to preserve blinding.
Prior to si te closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied 
drugs are returned t
othe sponsor or its designee for destruction. The invest igator or designee will 
retain a copy  of the docum entati on regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 42of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
9.0 STUDY PL AN
9.1 Study Procedures
The fo llowing sect ions describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same invest igator or site personnel whenever possible. The 
Schedule of Study  Procedures i s located in Appendix A.
9.1.1 Informed Consent Procedure
The requi rements of the informed consent process are described in Sect ion 15.2 and Appendix C.
Inform ed consent m ust be obtained prior to the subject entering into the study , and before any 
protocol -directed procedures are performed.
A unique subject ident ificat ion number (subject number) will be assigned to each subject through 
the IWRS system at t
he time that informed consent is obtained; this subject number will be used 
throughout the study .
9.1.2 Demographics, Medical History, and Medication History Procedure
Dem ographic informat ion to be obtained will include date of birth or age, sex, Hispanic 
ethni city (as applicable), race as described by the subject, height, weight, and smoking/nicotine 
usage status of the subject at Screening.
Medical history  to be obtained will include determining whether the subject has any  
significant condit ions or diseases re l
evant to the disease under study that resolved at or prior to 
signing of informed consent. Ongoing condit ions are considered concurrent medical 
condi tions (see Sect ion 9.1.16 ).
Medicat ion history  informat ion tobe obtained includes any medicat ion relevant to eligibilit y 
criteria stopped at or within 60 days prior to signing of informed consent .
In addit ion, all prior medication history for the treatment of UC/pouchit is,with the reason for 
discontinuat ion,is to be collected for subjects where possible.
9.1.3 Ulcerative Colitis and Pouchitis History
UC history  will include details of UC diagnosis, disease severit y, surgery  including IPAA date, 
hospi talizations, and extraintest inal manifestations.
9.1.4 Physical Examin ation P r o cedure
A Visit 1 (Screening) physical examinat ion will consist of the following body  systems: (1) ey es; 
(2) ears, nose, throat; (3) cardiovascular system; (4) respiratory  system; (5) gastr ointestinal 
system; (6) dermatologic system; (7) extremit ies; (8) muscul oskeletal  system; (9) nervous system; 
(10) lymph nodes; and (11) other. All subsequent physical examinat ions should assess clinically  
significant changes from the assessment performed prior to fi rst dose of study  drug. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 43 of 107Protocol Incorporating Amendment No. 04 14 September 2020
9.1.5 Weight, Height 
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. The Takeda standard for collecting height is centimeters without decimal places and for 
weight it is kilograms (kg) with 1 decimal place.
9.1.6 Vital Sign Procedure
Vital signs will include body temperature, respiratory rate, supine blood pressure (systolic and 
diastolic, resting more than 5 minutes), and pulse (resting more than 5 minutes).
When vital signs are scheduled at the same time as blood draws, the blood draw will take priority 
and vital signs will be obtained at least 0.5 hours before or after the scheduled blood draw.
9.1.7 PML Checklist
Site staff will administer the subjective PML checklist during Screening to exclude subjects with 
positive responses from enrolling into the study. The subjective PML checklist will be 
administered prior to dosing at each visit, as shown in  Appendix A,  to evaluate symptoms 
suggestive of PML. Any subjects reporting signs or symptoms of PML will unde rgo objective 
testing and may be referred to a neurologist for a full evaluation. The symptoms from a positive 
PML checklist obtained after randomization will be recorded as an AE. Additional information 
and tools will be found in the Investigator Site File.
9.1.8 ECG Procedure
A standard 12-lead electrocardiogram (ECG) will be recorded. The investigator (or a qualified 
observer at the study site) will interpret the ECG using 1 of the following categories: within normal 
limits, abnormal but not clinically significant, or abnormal and clinically significant. A copy of the 
ECG trace should be kept with the subject’s notes.
9.1.9 Primary Effica cy Measurement 
The primary efficacy measure is having achieved clinically relevant remission after 14 weeks of 
treatment. Clinically relevant remission will be  defined as a mPDAI score <5 and a decrease in 
mPDAI score of ≥2 points from Baseline.
9.1.10 Pouchitis Endoscopy
Endoscopy will be performed at Screening (baseline endoscopy), Week 14, and Week 34. 
All study endoscopies will be video-record ed using the Robarts Central Image Management 
Solutions (CIMS). All study videos will be subject to central review to ensure consistent grading. 
Central reviewer’s assessment will stand as fin al assessment for eligibility, if different from the 
site’s.
Central reviewers will score endoscopic findings by using a defined list of descriptors defined in 
the Endoscopy Image Review Charter. These include the mPDAI/PDAI descriptors. Additionally,
, number of ulcers (total, aphthous, and non-aphthous), and proportion of surface area Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use(sysystolicstoli
)..
draw wdraw w
eduled bduled b
ScreeninScreen
ive PMve PM
ppendixpendi
ymptommpto
ll evalueval
be recobe re
e FiFille.e
m (ECGm (EC
erpret pret tht
ally signlly sig
with the with the
cacy Mecacy M
acycymmyea
iccaallyllyry
e of of ≥2≥
PouchPouc
ndoscopdosco
All All stu
SolS
CCI
Vedolizumab IV
Study No. Vedolizumab-4004 Page 44 of 107Protocol Incorporating Amendment No. 04 14 September 2020
ulcerated (excluding aphthous ulcers) in the pouch will be scored for Screening, Week 14, and 
Week 34/Early Termination videos. 
At each endoscopy, a total of 4 to 5 pieces of biopsy will be obtained from the distal, mid, and 
proximal pouch body. Biopsies will be assessed for the presence of inflammation by trained, 
central histopathologists. Work Instructions will detail the requirements for study endoscopy, 
biopsy and histopathology. Subject preparation f or endoscopy should follow the site’s usual 
clinical practice (such as phosphate enema or polyethylene glycol). 
9.1.11 PDAI
The PDAI was developed as an objective, a nd quantitative criteria for pouch inflammation after 
IPAA. The 18-point overall score is calculated from 3 separate 6-point scales based on clinical 
symptoms (0 to 6), endoscopic findings (0 to 6) and histologic changes (0 to 6). The PDAI 
incorporates histologic features of acute inflammat ion, along with symptom and inflammation on 
endoscopy, and establishes a cutoff of 7 for differentiation between ‘pouchitis’ ( ≥7 points) and ‘no 
pouchitis’ (<7 points) [33]. See Appendix E.  
Clinically relevant remission in this study is defined as a PDAI score <7 and a reduction of ≥3 
points compared to Baseline. 
Although the standard PDAI remains an optimal way to diagnose pouchitis, the mPDAI, 
consisting of symptom and endoscopy scores from the PDAI but omitting histology scores, offers 
similar sensitivity and specificity in diagnosing patients with acute or acute relapsing pouchitis. A 
cutoff of 5 differentiates patients with pouchitis (mPDAI ≥5) from patients without pouchitis 
(mPDAI <5) [34]. See  Appendix F.
Clinically relevant remission in this study is defined as an mPDAI score <5 and a reduction of ≥2 
points from Baseline.
A partial response is defined as a reduction of mPDAI score of ≥2 points from Baseline.
The clinical part of the PDAI score (patient reported symptoms) will be assessed as the average 
from the 3 days immediately prior to Baseline endoscopy (or bowel preparation for endoscopy). 
Recording will be facilitated by a paper diary.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Used, 
copycopy , , 
usualsual
uch inflah inf
scalscales bes
ges (0 tges (0
h sympsymph
ween ween ‘‘p
a PDAIPDA
l wayway toyy
frorom thm 
osing paosing 
pouchitouchit i
his stuhis st d
ned as aed as
he PDAIe PDA
mmediatmedia
be facilbe fac
operty of Takeda: F
Vedolizumab IV
Study No. Vedolizumab-4004 Page 45 of 107Protocol Incorporating Amendment No. 04 14 September 2020
9.1.14 Patient Reported  Outcome Measures
Subjects will complete the IBDQ and the CGQL quality of life questionnaires at the time points 
specified in the schedule of events (Appendix A) . 
9.1.14.1 IBDQ
The IBDQ is a valid and reliable [ 37-39] instrument used to assess quality of life in adult patients 
with IBD. It includes 32 questions on 4 domains of Health-Related Qu ality-of-Life (HRQOL): 
Bowel Systems (10 items), Emotional Function (12 items), So cial Function (5 i tems), and
Systemic Function (5 items). Subjects are asked to  recall symptoms and quality of life from the last
2 weeks and rate each item on a 7-poi nt Likert scale (higher scores e quate to higher quality of life). 
A total IBDQ score is calculated by summing the score s from each domain; the total IBDQ score 
ranges from 32 to 224. See  Appendix I.
9.1.14.2 Cleveland Global Quality of Life (C GQL) Instrument (Fazio Score)
The CGQL (Fazio Score) was developed as a quality-of-life indicator specifically for patients with 
ileal pouch-anal anastomosis [40]. Subjects rate 3 items (current quality of life, current quality of 
health, and c urrent energy level), each on a scale of 0 to 10 (0, worst; 10, best). The scores are 
added, and the final CGQL utility score is obtained by dividing this result by 30 [40].
Fazio score will be assessed as the average from 3 days immediately prior to endoscopy (or bowel
preparation for endoscopy). Recording will be facilitated by a paper diary.
9.1.15 Documentation of Concomitant Medications
Concomitant medication is any drug given in additi on to the study drug. These may be prescribed 
by a phys ician or ob tained by the subject over the counter. Concomitant medication is not provided 
by the sponsor (including ciprofloxacin). At each study visit, subjects will be asked whether they 
have taken any medication other than the st udy drug (used from signing of informed consent 
through Week 48), and all medication including vitamin supplements, over-the-counter 
medications, and oral herbal preparations, must be recorded in the eCRF.
9.1.16 Documentation of Concurrent Medical Conditions
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at signing of informed consent. This includes clinically significant laborat ory, ECG, or physical 
examination abnormalities noted at Screening/baseline examination, according to the judgement 
of the investigator. The condition (ie, diagnosis) should be described as current on the Medical 
History eCRF.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Tet tt thehetimti
qualitqualit y
ted Qd Qua
ocial cial FuF
ymymptomptommmm
gher scoher sc
oreres froms fr
CGQL) GQL)
as a quas a q
ubjects rbject
each on ach on
ity y scoresco
as as ththe
py). Rec). Reyyse
ation ofion o
eedicatdicat io
an or n orob
onsor (insor (
aken anaken an
oughughWW
medicatedica
9.19Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 46of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
9.1.17 Procedures for Clinical Laboratory Sam ples
All samples will be collected in accordance with acceptable la boratory  procedu res. The maximu m 
volume of bloo d at any  single visit is approximate ly 20mL, and the a pproximate total vo lume of 
blood for the study  is 75mL. Details of these procedures, s pecim enhandling and requi red saf ety 
monitoring will be given in th e laboratory  manual. 
Table 9.a Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
RBC
WBC with differential*
Hemoglobin
Hem atocrit
Platelets
PT/INRALT
Albumin
Alkaline phosphatase
AST
Total bilirubin
Total protein
Creatinine
Blood urea nitrogen
Creat ine kinase
GGT
Potass ium
Sodium
Calcium
Chloride
Magnesium
Phospho rus
Uric Acid
GlucoseBilirubin
Blood
Glucose
Ketones
Leukocy te esterase
Nitri te
pH
Protein
Specific Gravity
Other:
HIV
Hepat itis panel, incl uding HBsAg and anti -HCV
Serum Urine Stool
QuantiFERON for TB
CRP hCG (for pregna ncy in female 
subjects of childbearing potential only)Fecal 
calprotecti n 
beta hCG ( for pregnancy in female su bjectsof 
childbearing potential only)
FSH, if menopause is suspected (Screening visit o nly)C diffici le
*WBC differential to include lymphoc ytes, monocytes, basophils, eosinophils, and neutrophils.
FSH =follicle -stimulating hor mone, GGT= γ -Glut amyl tran sferase, hCG =human chorionic gonadotropi n, 
PT=prothrombi n time, RBC=red blood cells.
The central  laboratory will perform  laboratory  tests for hematology, serum chemistries, stool, 
urinalysis, and Quant iFERON for TB. The results of laboratory  tests will be returned to the 
investigator, who is res ponsible for rev iewing and filing these results .
If subjects e xperience ALT or AST >3 ×ULN, follow -up laboratory  tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, tot al bilirubin, G GT, an d INR) sho uld be pe rformed wi thin a 
maximum o f 7 day s and pr eferably wi thin 48-72 hours after the abnormali ty was noted.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 47 of 107Protocol Incorporating Amendment No. 04 14 September 2020
(Please refer to Section  7.4for discontinuation criteria, and Section  10.2.3 for the appropriate 
guidance on Reporting of Abnormal Liver Function Tests in relation to ALT or AST >3 ×ULN in 
conjunction with total bilirubin >2 ×ULN.)
If the ALT or AST remains elevated >3 ×ULN on these 2 consecutive occasions the investigator 
must contact the medical monitor for consider ation of additional testing, close monitoring, 
possible discontinuation of study  drug, discussion of the releva nt subject details and possible 
alternative etiologies. The abnormality should be rec orded as an AE (p lease refer to Section  10.2.3
Reporting of Abnormal Liver Function Tests for reporting requirements).
9.1.19 Clostridium Difficile Sample Collection
A stool sample will be collected during Screening for the analysis of C difficile .
9.1.20 Tuberculosis Screening
All subjects will complete TB screening to d etermine eligibility as described in Section  7.2.2,  
unless a negative test result is available from within  3 months prior to Screening and subject has no 
risk factors for exposure. All subjects must complete a diagnostic test during Screening either a 
QuantiFERON test or a tuberculin skin test. Subjects will be excluded from the study if they have 
active or latent TB, regardless of treatment history.
9.1.21 Contraception and Pregna ncy Avoidance Procedure
9.1.21.1 Male Subjects and Their Female Partners
From signing of informed consent, throughout the duration of the study, and for 18 weeks after last 
dose of study drug, nonsterilized** male subjects who are sexually active with a female partner of 
childbearing potential* must use barrier contraception (eg, condom with spermicidal cream or 
jelly). In addition, they must be advised not to donate sperm during this period. Females of 
childbearing potential who are partners of male subjects are also advised to use additional 
contraception as shown in the list contain ing highly effective contraception below.
9.1.21.2 Female Subjects and Their Male Partners
From signing of informed consent,  throughout the duration of the study, and for 18 weeks after last 
dose of study drug, female subjects of childbearing potential* who are sexually active with a
nonsterilized male partner** must use a highly effective method of contraception (from the list 
below). 
In addition, they must be advised not to donate ova during this period.CCI
Property of Takeda: For Non-Commercial Use Only and Subjeche analye ana
teerminermin
m wwitithinh
uststcocom
in test. n tes
reatatmenme
Pregnanregna
and and TheT
formedrmed
ug, nonsug, non
potentotent iai
ddition, dition
rirng pong p
raceptionaceptiplicable Terms of Usegator ator 
g, g, 
ossible ossible
SectionSectio
9.1.21.21.21
FroFect to the Appli
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 48of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
9.1.21.3 Definitions an d Procedures for Contraception and Pregnancy Av oidance
The follo wing definitions ap ply for contracepti on and pregnancy avoidance procedures.
* A wom an is considered a woman of childbearing p otenti al (ie, fe rtile) fo llowing m enarche and 
until becoming post -menopausal unles s perm anently  sterile. Permanen t sterilizat ion methods 
include hyst erectomy, and bilat eral oophorectomy . A postmenopausal state is defined as no 
menses for 12 months wit hout an alt ernative m edical  cause. A high fo llicle st imulat ing hormone 
(FSH) level in t he postmenopausal range (FSH >4 0 IU/L) m ay be us
ed to confirm a 
post-menopausal state in younger wom en (ie, younger than age 45) or women who are not using 
hormonal contracep tion or hormonal replacem enttherapy. However, in the absence o f 12 m onths 
of amenorrhea, a single FSH measuremen t is insufficie nt.
** Sterilized mal es should be at lea st 1 year post -bilateral vasectomy and have confirmed that they 
have obta ined documentat ion ofthe absen ce of spe r
min the ejaculate or have had bilateral
orchi dectomy .
The follow ing procedures apply f or contraception and pregnancy avoid ance.
1.Highly effect ive methods of contraception are defined as “those that, alone or in comb ination, 
resul tin a low failure rate (i e,less than 1% failure rate per y ear whe n used consisten tly and 
correctly ). In this stu dy, where medic ations and devices co ntaining hormones are included, the 
only acceptable methods of contraception are: 
Non-horm onal methods:
Intraute rine devic e (IUD). 
Bilateral  tubal  occl usion. 
Vasectomised partner (provi ded that partner is the sole sex ual partner of the trial 
participant and that the vasec tomised partner has received medical assessment of 
the surgi cal success).
Horm onal methods:
Combined (e strogen a n
dprogestogen) hormonal contraception as sociated wi th 
inhibition of  ovul ation initiated at least 3 m onths prior to the firs t dose of study  
drug OR combined wit h a barrier method (male condo m, female condom or 
diaphragm) if for sho rter d uration un til she h asbeen on contraceptive for 3 months;
Oral.
Intravaginal (eg, ring).
Transdermal.
Proge stogen -only hormonal contraception a ssoci ated wi th inhibition of  ovul ation 
initiated at least 3 months prior to the first dose o f study  drug OR combi ned wi th a
barrier method (m ale condom , female condo m or dia phragm ) if short er until she 
has been on contra ceptive for 3 m onths;
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 49of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Oral. 
Injecta ble.
Implantable.
2. Unacceptable methods of contraception are:
Periodic abst inence (eg, calend ar, ovul ation, symptoth ermal, post-ovulation methods).
Spermicides only .
Withdraw al.
No m ethod at all.
Use of female and male co ndoms together.
Cap/di aphragm/sponge without spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of con tracepti on.
3.Subjects will be pr ovided wi thinformation on highly effect ive method s of contracepti on as 
part of the subject infor med consent pro cess and will be aske d to si gn a consent form stating 
that they  understand the requirements for avo idance of preg nancy , donat ionof ova, and spe rm 
donati onduring the course of the study .
4.During the course of t he study, regular urine human c horionic gonado tropin (hCG) pregnanc y 
tests will be per formed only for women of childbearing potential and all subjects (male an d 
female) will receiv e continue d gui danc e with respect to the avo idance of pregna ncy and sperm 
donation as part of the study pro cedures. Such g uidance should includ e a reminder of the
following:
a.Contraceptive requirements of the study .
b.Reasons for use of b arrier m ethods (ie, c ondom ) in males wit h pregnant partners.
c.Assessment of subjec t com pliance thr ough questions such as:
i.Have yo u used the cont raception consistent ly and correctly  since the l ast 
visit?
ii.Have y ou forgotten to use contraception since the last visit?
iii.Are yo ur men ses late ( even in w o
men with irregular or infrequent menstru al 
cycles a preg nancy test must be performed if the answer i s “yes”)?
iv.Is there a ch ance y ou coul d be p regnant ?
5.In addit ion to a negative serum hCG pregnancy test at Screening, female subject s of 
childbearing potenti almust al so have confirmed menses in the month before fi rst dosing (no 
delayed menses) and a negat ive urine hCG pregnancy t est prior to receiv ing each IV dosing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 50of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
9.1.21.4 General Guidance With Respect to the Avoidance of Pre gnancy
Such gui dance shoul d inc lude a re minder of the following:
Contraceptive re quirements of th e study .
Reasons for use of bar rier methods (i e,condom ) in males w ith pregnant partne rs.
Assessment of subject compliance through questions such as:
oHave you used the contra ceptio n consiste ntly and c
orrectly  since the l ast visit ?
oHave y ou forgotten to use contraception since the last v isit? 
oAre your menses l ate (even in women wit h irregul ar or infrequent menstrual cycles 
a pregnancy  test m ust be perform ed if t he answer is “y es”)
oIs there a chance yo u could be pregnant ?
9.1.22 Pregnancy
If any subject is found to be pregnant during the study s he shoul d be wi thdrawn and 
sponsor -supplied treatment s hould be immediately  discontinued. In addit ion, any  pregnancies in 
the partner of a male subje ct during the study orfor 18 weeks after the last dose, sho uld also be 
recorded fo llowing authori zation from the subject’ s partner.
If the pre gnancy  occurs durin g administrati on of  active study  drug, eg, after Visit 1 or within 18 
weeks of the last dose o f active s tudy drug , the pregnancy should be reported immedi ately , using a 
pregnancy notificat ion form, to the contact lis ted in Section  1.0.
Shoul d the pregnancy  occur during or after admin istrati on of  blinded drug, the invest igatormust 
inform  the subject of their righ t to receive tre atment information. If the subj ect chooses to receive 
unblinded tre atment inform ation,the individual blind should be broken by the invest igator. 
If the femal e subject and/o r fema le partner of a mal e
subject agrees to the primary care phys ician 
being info rmed, the invest igator should n otify the prima rycare physician tha t the subject/femal e 
partner of the subject was participat ing in a clinical study  at the tim e she became pr egnant and 
provi de detail s of the study  drug the subject received (blinded or unbl inded, as applicable).
All preg nancies, includ ing female partners o f male subjects, in subjects on active study  drug 
including placebo will be fo llowed up to f inal outcome, u sing t he pregnan cy form. Pregnancies 
will remain blinded to the study team. The ou tcome, including any premature terminat ion, mu stbe 
reported to the sponsor. An evalua tion after the bi rth of the child will also be conducted.
9.1.23 Documentation of Screen Failur e
Invest igators must acco untfor all subjects who sign informed co nsent.
If the su bject is found to be not eligib le, the invest i
gator shoul d com plete the eCRF. The IWRS
shoul d be contacted as a notificat ion of screen failure.
The primary  reason for screen failur e is recor ded in the e CRF using the fo llowing categori es:
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 51of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
1.PTE/AE.
2.Did not m eet incl usion criteria or di d me et exclusion cr iteria (specify  reaso n).
3.Significant pro tocol  deviat ion.
4.Lost to follow -up.
5.Voluntary  withdrawal (specify  reason) .
6.Study  termina tion.
7.Other, spe cify.
Subject numbers assigned to subjects who fai l screening shou ld not be reused.
9.1.24 Documentation of Randomizati on
Randomization will be perform ed throu gh the IWRS system. Only subjects who meet all o f the 
inclusio n criteria and none of the exclu sion cri teria are e ligible for randomizat ion into the 
treatm ent phase.
9.2 Monit oring Subject Treatment Complia nce
A study  drug dispensing log, inc luding records of drug received fro m the sponsor and vo lume of 
vedo lizumab dispensed to each subject intrav enousl y, will bemaintain ed by the site. 
If a subject is persiste ntly nonco mpliant with the study drug, it may b e appropriate t o withdraw the 
subjec t from the study . 
9.3 Schedule of Observations and Procedures
The schedule for all study -relate d procedures fo r all evaluat ions is show n in Appendix A.
Assessments should be co mpleted at the design ated visit/time po int(s).
9.3.1 Screening 
Subjects will be screened within 28 days pri or to randomizat ion. Subjects wi ll be screened in 
accordance wi th predef ined inclusi on and exclusio n criteria as described in Sec tion7.0.  See 
Secti on 9.1.23 for procedures for documenting screening f ailures.
Proced ures t o be com pleted at S creening (Visit 1) can be found in the Sc hedule of Study  
Procedures ( Appendix A). 
9.3.2 Rescreening
Autom atic rescreening of a subject is not allowed. If the principal invest igator believes in th e 
appropriatenes s of the 
subject for the study and considers a res creen, permissio n for the same must 
be obtained from the medic almonitor. Rescreeni ng at the invest igator’s discreti on wi thout prior 
approval  from the m edical mo nitor is not p ermitted. Rescr eening can be do ne only o ncefor a 
patient.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 52of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
There i s a minimum of 28 days from ini tial screening before rescreeni ng can be done.
If C difficile eradi cation is done, a m inimum o f 28 days after end of therapy  is requi red before 
rescreening. 
All inclusio n and excl usion cri teria must bemet again at Rando mizat ion. 
If a pat ient was randomi zed, no rescreening or re -enrollment is possible .
9.3.3 Study Randomizati on 
Randomization w ill take place on Day  1. The Day  1 procedures are documented in Appendix A.
If the subject has sat isfied all o f the inclusio n criteria and none o f the exclusio n criteria for 
randomizat ion, the subject should be ran domized using the IWRS as described in Section 8.2. 
Subject s will be i
nstructed on when the first dose of stu dy drug will be given as described in 
Secti on
 8.1.3 . The procedure for document ing Screening failures is provided in Section 9.1.23 . 
9.3.4 End of Treatment Visit
The End of Treatm ent (EOT) Visit will be performed at Wee k 30.
9.3.5 Final End oscopy Visit or Early Termination
The Fi nal Endoscopy  Visi t will  be perform ed at Week 34 or at ET.
For all subjec ts receiving st udy drug, the invest igato r
must com plete the End of Study  (EOS) 
eCRF page.
9.3.6 Safety Follow -UpVisit
Follow-up will begin the first day after the Final Endoscopy  Visit or Early Terminat ion Visit and 
will cont inue for 18 weeks post -treatment unt il Week 48. If subjec t is m ale or subjec t is 
postm enopausal and cannot attend the site for thi s visit, the visit may be conducte d via phone.
9.3.7 Post-Study Follow -Up
Upon complet ion of or early termination fro m the study, all subjects will co mplete a LTFU saf ety 
survey by  telepho ne. Thi s questi onna irewill be administered at 26 weeks afte r the l ast dose of 
study  drug.
9.3.8 Unscheduled Visi ts Due to Exace rbation/Relapse of Po uchitis
Subjects who are seen by the invest igator or site staff at a time point not required by the protoco l 
(ie,unschedul ed visit) due to disease exacerbat ion will undergo the following:
1.Physical examinat ion.
2.
Urine pre gnancy  test (f or females of childbea ring potenti al).
3.Clinical chemistry  and hematol ogy, if indicated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 53of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4.Concomitant medicat ions.
5. A E/SAE assessmen t.
9.3.9 Post-Study Ca re
Vedoli zumab IV will  not be supplied upon comple tion of  the subj ect’s parti cipat ion in the stud y. 
The subject should be returned to the care of a phys ician and standard therapies as required.
Subject to applicable laws and feasibili ty and Taked a’s decisi on, acces s to the study drug may  be 
available to i ndividual subjec ts for whom  no standard therapy exists, and th e subject is at risk of 
significant m orbidity or mortali ty.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 54of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
10.0 PRETREATMENT EVENTS (PTE) AND ADVERSE EV ENTS (AE)
10.1 Definitions
10.1.1 PTEs
APTE i s defined as any  untoward medical occurrence in a clinical i nvest igation subject who has 
signed inform ed co nsent to partic ipate in a study  but prior to administra tion of  any study  drug; i t 
does not necessarily  have to have a causal rel ationship wit h study  participat ion.
10.1.2 AEs
AnAE is defined as any untoward medical occurrence in a clinical invest igation subject 
administered a drug; it does not nec essarily have to ha ve a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unint ended sign (eg, a c linically significant abnormal 
laboratory value), symptom , or disease temporally associa ted with the us e of a drug whether o r not 
it is conside red rel ated to the drug.
10.1.3 Product Complaints
A product complaint (PC) is a verbal, writte n, or electronic expressi onthat implies dissat isfaction 
regarding the identi ty, strength, puri ty, quali ty, or s tabilit y of a drugproduct and/or device 
(eg,prefilled syringe).
An invest igator who is made aware of or ident ifies a potential PC shoul d immed iately report th e 
event t o Takeda in accordance with the contact l ist provided to the site. Whenever possible, th e 
associ ated pr oduct should be maint ained in accordance with the instructi ons pending further 
guidance fro m a Takeda representat ive.
10.1.4 Additional Point s to Consi der for P TEs and AEs
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a pr e-exist ing condit ion.(Intermittent 
events for preexi sting condit ions or underlying disease should not be conside red PTEs or 
AEs.)
Necessitate t herapeuti c intervent ion.
Requi re an invasive diagn ostic procedure.
Requi re discont inuat ion or a c hange in dose o f study  drug or a con comitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
PTEs/AEs caused by a stu dy pro cedure (eg , a bruis e after blood draw) should be recorded as a 
PTE/AE.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 55of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Diagnoses vs signs and symptoms:
Each event should berecorded to repres ent a single diagno sis. Acco mpanying signs 
(including abnormal laboratory  values or ECG find ings) or sympto ms sho uld NOT be
recorded asadditional AEs. If a diagnosi s is unk nown, sign(s) or symptom(s) should be 
recorded appropriately a s a PTE(s) or as an A E(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG finding s are o nly considered to be PTEs or AE s if they
are judged to be clinically significant (ie, if so me act ion or i ntervent ion is required or if the 
investigator j udges the c hange to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  or ECG re- testand/or continu ed mon itoring of an abnor malvalue or finding are not 
considered a n interventi on. In addit ion, repeated or additi onal noninvasive testing for 
verific ation, evaluat ion or monitoring o f an abnormalit y is not consi dered an intervent ion.
If abno rmal laboratory values or ECG f indings a rethe result of pathology for which ther e is an 
overall diagnosis (eg, increased creat inine in renal f ailure), the diagnosi s only  should be 
reported appropriately  as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-existing condit ions (p resent at the time ofsigning of informed consent) are consi dered 
concurrent medical condi tions and shoul d NOT be recorded as PTEs or AEs. Base line 
evaluat ions (e g, laboratory  tests, ECG, X -rays etc.) should NOT be recorded as PTEs unl ess 
related to study procedures . However , if the subject experiences a worsening or com plicat ion 
of such a concurrent medical co ndition, the wo rsening or complicat ion shoul d be record ed 
appropriately  as a PTE (worsening or complication occurs before start of study drug) or an AE 
(worsening or co mplication occurs after start of study  drug). Invest igato rs should ensure that 
the event term recorded captures the change i n the condit ion (eg , “worsening of…”).
If a subject has a pre -exist ing episodic concurrent m edical condit ion (eg, asthma, e pilepsy) 
anyoccurrence of an episode should only be captured as a PTE/AE if the condit ion beco mes 
more frequent , 
serious or severe i n nature. Invest igators shoul d ensure that the AE term 
recorded captures the change in the c ondition from B aselin e (eg, “wo rsening o f…”).
If a subject has a degenerat ive con current medical condi tion (eg, cataracts, rheum atoid 
arthri tis),worsening o f the condition shoul d onl y be recorded as a PTE/AE if occurring to a 
greater extent to that which woul d be expect ed. 
Worsening o f PTEs or A
Es:
If the subject experiences a worsen ing or com plicat ion of a PTE after starting adm inistrati on 
of the study  drug, the w orsening or complic ation shoul d be recorded appropriately  as an AE. 
Invest igators should ens ure that the AE term recorded c aptures t hechange in the condit ion 
(eg, “worsenin g of…”).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 56of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
If the subject experiences a worsening or com plicati on of an AE after any  change in study  
drug, the worsening or complicat ion shoul d be recorded as a new AE. Invest igators shoul d 
ensure t hat the AE term recorded captures the change in the condit ion (eg, “worsenin g of…”).
Changes in intensit y of AEs /Serious PTEs:
If the subject experiences changes in 
intensity of an AE/seri ous PTE, the event should be 
captured once wit h the m aximum i ntensity recorde d.
Prepl anned procedures (surgeries or intervent ions)
Prepl anned p
rocedures (surgeries or therapi es) that were s cheduled pri or to si gning of 
inform ed co nsent are not considered PTEs or AEs. However, if a preplanned procedure is 
perform ed ea rly (eg, as an e mergency) due to a worsening of the pre- exist ing c ondition, the 
worsening of the condit ion shoul dbe recorded as aPTE or an AE. Comp lications result ing
from any planned surgery  shoul d be reported as AEs.
Elect ive surgeries o r procedures:
Elective procedur es perfor m
edwhere there i s no change in the subje ct’s m edical con dition 
shoul d not be recorded a s PTEs or AEs, but shoul d be docum ented in the subject’ s source 
docum ents. Com plicat ions result ing from an elect ive surgery shou ld be reported as AEs .
Insuffic ient clin ical response (lack of efficacy):
Insuffi cient clinical response, efficacy, or pharmacol ogic act ionshould NOT be recorded as 
an AE. The inves tigator m ust m ake the di stinction between exacerbation o f pre-exist ing 
illness and lack of therapeut ic efficacy.
Over dose:
Cases of overdose with any  medication wi thout m anifested side effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any  
manifested side effects will be cons idered PTEs or AEs an d will  be recorded o n
the AE page 
of the eCRF.
10.1.5 SAEs
An SAE i s defined as any untoward m edical occurrence th at at any  dose:
1. R esults in DEATH.
2.IsLIFE THREATENING.
The term “life threatening” refers to an event in which the subject was a t risk of death at the 
time of the event; itdoes not refer to an event that hypo thetically  might have caused death 
if it were m ore severe.
3.Requires inpat ient HOSPI TALIZATION or prolo ngati on of  exist ing hospitalizat ion.
4.Results in persistent or significant DISABILITY/INC APACIT Y.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 57of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
5.Is a CO NGENITAL A NOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MED ICAL EVENT that s atisfies any of the fo llowing:
May require in tervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not imm ediately life 
threate ning or fa tal or doe s not resul t in hospitalization.
Include s any event or sy nonym described in the Takeda Medically  Signi ficant AE List 
(Table 10.a).
Table 10.a T akeda Medi cally Sign i ficant AE List
Term
Acute respiratory failure/acute res piratory  distress 
syndromeHepatic necrosis
Torsade de pointes / ventricular fibrill ation / ventricular 
tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hype rtension Acute r enal failu re
Convulsive seizure Pulmonary hyperte nsion
Agranulocy tosis Pulmonary fibrosis 
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens -Johnson syndrome Confirmed or suspected transmission of infec tious agen t by a 
medicinal product
Neuroleptic malignant s yndrome / maligna nt hy perthermia
Spontaneous abortio n / stil lbirth and fetal deat h
PTEs that fulfi ll 1 or more of the serious criteria above are also to be considered SAEs and should 
be report ed and fo llowed up i n the same manner (see Sections 10.2.2 and10.3).
10.1.6 AEs of S pecial Interest
An AESI (serious or nonserious) is an AE of scientific and medical conce rn specifi c to the 
compound or program , for whi ch ongoing mo nitoring and rapi d communicat ion by the 
investi gator to Takeda may be appropri ate. Such events may req
uire f urther invest igation in order 
to characterize and understand them a nd would be des cribed in protoc ols and in structions provided 
for invest igators as to how and when they shoul d be reported to Tak eda.
AESIs for this compound are ser ious infections inc luding opportunist ic infect ion such as PML, 
liver injury , malignancies, i nfusio n-related or sy stemic rea ctions and hypersensi tivity, as 
described in furth er detail below.
Injection and/or Infusion Site Reactions and Hypersensitivity 
Currently, there is no evidence to support the routine prophylactic administration of premedica tion 
(eg, antih
istami nes, corti costeroi ds) to subjects receiving vedo lizumab; hen ce such 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 58of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
prem edica tions are unlikely to be neces sary or benefic ial. At the di scret ion of the invest igator, 
however, subjects may  be administered premedicatio n prior to any  stud y drug administ ration. 
Corti costeroids, if given as a premedicat ion, should be li mited to the day  of administrati on. 
Vedolizuma b IV should be administered by a hea lth care practit ioner prepared to m anage 
hypersensit ivity react ions including anaphylaxis, i f they occur. A ppropr iate monit oring and medical 
support measure should be availa ble for immediate use. Subjects should be obser ved for 2 hours
following the first 2infusio ns, at a m inimum, and 1 hour after each subsequent infusio n.
Subjects and caregiver s will be instr ucted to report the develo pment of rash, hives, pruritus, flushing , 
urticaria, inje ctions si te pain, redness, and /or swelling, e tc. that may represen t an 
administration -related reaction (ie, infusio n-related reaction) to study drug. Subjects will be asked to 
report admini strati on-related AEs to the si tes immedi ately as t hey are experienc ed. Appropri ate 
treatm ent and follow-up will bedetermined by  the investigator. If si gns or symptoms of an 
administration -related reacti on are observed during the administra tion of study  drug, i t sho uldbe 
immediately  discontinued and the subject treated a s medically appropriate. In th e case of a mil d 
reacti on, study  drug administrati on m ay be reinit iated (with appropriate premedicat ion and 
investigator supervi sion) at the di screti on of  the investigat or.Subjects with a severe or serious 
administration -related reacti on (eg, shortness of breath, wheezing, stri dor, angi oede ma, 
life-threatenin
g change in vital signs, severe injection site reactions) must be withdra wn from the 
study (se e Invest igator Si te Fil e). 
In all cases of administration -related reacti on, the medical mo nitor must be in formed as soon as
practi cal. The dis position of  subject s with less severe administration -related reacti ons shoul d be 
discussed w ith the m edical monitor.
Seriou s Infections
Subjects will be mo nitored for si gnsand symptoms of infect ion and for lymphopenia during the 
study.Subjects with signs and symptoms sugg estive of infect ions, including GI infect ions, will be 
treated as clinica lly indicated. Interv entions ma y include antibiotic treatment, if appropriate and /or 
discontinuat ion of  concomi tant immunom odulators. Bl ood, sp utum, urine, and/or s tool cultures 
shoul d be obtained as appropriate for the detection and diagnosis of infection . Withhol ding o r 
terminating st udy drug a dministrati on m ay be considered as descr ibed in Sect ion 7.4.
Malignancies
All cases of maligna ncies that are dete cted during the study will be reported as AEs. Local medica l 
practi ces for the managemen t of malignances will appl y.Subjects with history  of malignancy 
(except for specif ic cancers) or at high risk fo r malignancy wi llbe excluded from t he study per the 
exclusi on criteria. 
Other 
Other special interest AEs include liver injury and PML, which are d iscussed i n Sections 10.2.3
and 11.2.1 , respectively.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 59of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
10.1.7 Intensity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as f ollows:
Mild: The event i s transien tand easily  tolerated by  the subject.
Moderate: The eve nt causes the subject discomfo rt and interrup tsthe subject’s usua l activities.
Seve re: The event causes considerable interference with the subject’s usual a ctivities.
10.1.8 Causality of AEs
The relationship of each AE to study  drug(s) will be assessed using t he following categori es:
Relat ed: An AE that follows a reasonable temporal sequence f rom administration of a drug (including the 
course after withdrawal of th e drug), or for whichpossible involvemen t of the drug cannot be 
ruled out , altho ugh factors other than the drug, such as underl ying diseases, complications, 
concom itant medicatio ns and concurrent treatments, may also be responsible.
Not Related: An AE th at does not fol low a reasonable temporal sequence from administration of a drug and/or 
that can re asonably be explained by other factors, such asunderlying disease s, complications, 
concomitant medications and concurrent treatments.
10.1.9 Relationship to Study Procedures
Relationsh ip (causal ity) to st udyprocedures should be determined for all PTEs and AEs.
The relationship should be as sessed as Relat edif the investigato
r considers that th ere is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relationship sho uld be ass essed 
as Not Related. 
10.1.10 Start Date
The st art date of the A E/PTE is the date that the fir st signs/sympto mswere noted by  the subject 
and/or inve stigator, and the time, if available.
10.1.11 Stop Date 
The stop date of the AE/ PTE is the date at wh ich the su bject reco vered, the event resolved but with 
seque lae or the subjec t died, and the time, if avail able.
10.1.12 Frequency
Episodi c AEs/PTE (e g, vomit ing) or tho se which occur repeatedly over a period of consecutive 
days are intermitt ent. All other events are conti nuous.
10.1.13 ActionConcerning Study Drug
Drug withdrawn –a study  drug i s stopped due to the particula r AE.
Dose not changed –the particu lar AE did not requ ire stopping a study drug.
Unknown –only to be used if it has not been p ossible to dete rmine what actio n has been t
aken.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 60of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Not Applicable –a study  drug wa s stopped for a r eason other than the particula r AE eg, the 
study has been terminat ed, the subject die d, dosing wi th study  drug was al ready stopped 
before the onset of the AE.
Dose Interrupt ed –
the dose wa s interrup teddue to the particular AE.
10.1.14 Outcome
Recovered/Resolved –Subject returned to first as sessment status with respect to the AE/PTE.
Recovering/ Reso lving –the intensit y is lowered by  1 or m ore stages: the diagnosis o r 
signs/symptom s has almo st dis appeared; theabnormal laboratory value improved, but has not 
retur ned to the normal range or to baseline; the s ubject di ed from a cause other than the 
particular AE/PTE with the condit ion rem aining “recovering/reso lving”.
Not recovered/not resol ved –there is no ch a
nge in the diagnosis, signs or symptoms ; the 
intensity of the diagnosis, signs/ sympto ms or laborator y value on the last d ay of the observed 
study  period has got worse than when it started; is an irreversible conge nital anom aly; the 
subject di edfrom anoth
ercause with the particular AE/PTE sta te rem aining “Not
recovered/not resolved”.
Reso lved with seque lae –the subject rec overed from an acut e AE/PTE but was left with 
perm anent/si gnificant impairment (eg, recovere d from  a cardi ovascul ar acci dent but wi th
some persisting paresis).
Fatal  –the AEs/PTEs which are considered as the cause of de ath. 
Unknown – the course of the AE /PTE cannot be foll owed up due to hospi tal change or 
residence change at the end of the subj ect’s parti cipation in the stud y.
10.2 Procedu res
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTE and AE Collection Period
Start of PTE collect ion:
Collect ion of PTEs will  commence from the time the s ubject si gns the inform ed consent to 
participate in the study and continu e unt il the sub ject is first ad ministered study drug (Day 1; Visit  
2) or until sc reen failure. For subjects who discont inue prio r to study drug administration, PTEs are 
collected unt il the subject di scont inues study  parti cipat ion.
Start of AE collection: 
AEs must be col lected from the time that thesubject is first administered study drug (Day 1; 
Visit2). Any drugs provided by  the sponsor are c onsidered study  drugs , including pl acebo .
Routine co llection of AEs will continue unt il Week 48 (Vi sit 10).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 61of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
10.2.1.2 PTE a nd AE Reporting
1.Event term.
2.Start and sto p date, and time (if available).
3.Frequen cy
4.Intensit y
5.Inve
stigator’s opinio n of the caus al relat ionship between the event an d administration of study 
drug(s) (related or not related) (not completed for PTEs).
6.Invest igator’s opinio nof the causal r elationship to study  procedure(s), including the d etails o f 
the sus pected procedure.
7.Action conce rning study  drug (not applicable for PTEs).
8.Outcom e of event.
9.Seriousness.
PDAI and QOL instruments will not be used as a primar y means to coll ect AE s. However , should 
theinvest igator become aware of a potent ial AE through th e inform ation collected with t his 
instrum ent,proper follow- up wi th the subject for m edical evaluat ion shoul d be undertaken. 
Through this fo llow-up if it is d etermined that an AE not previo usly repor tedhas been ident ified, 
norm al reportin g requi rements sh ould be applied.
10.2.1.3 AEs of Special Interest
If an AE of special inter est, whi ch occurs d uring the treatment period or the follow -up peri od, is 
considered to be c linically signi ficant based on the criter iain Sect ion 10.1.6 , it should be recor ded 
in an AE of special interest eCRF or SAE Form . The ap
plicable form  shoul d be co mpleted and 
reported to the SAE reporting conta ct in Sect ion 1.1within 24 hours.
10.2.2 Collection and Rep orting of SAEs
When an SAE occ urs through the AE collecti on peri odit shoul d be repor ted according to the 
following procedure:
A Takeda SAE eCRF or form must be co mpleted, i n Engl ish and si gned by th e invest igator 
immediately  or wi thin 24 hours of first on set or notification o f the eve nt. The informa tion shoul d 
be co mpleted as fully  as pos sible but con tain, at a minimum:
A short descript ion of the event and the reason why the event is catego rized as s erious.
Subject identificat ion number.
Invest igator’s nam e.
Nam e of the study  drug(s).
Causalit y asses sment.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 62of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
The SAE eCRF s hould be co mpleted within 24 hours of first onset or notification o f the event. 
However, as a back -up, if r equired, the SAE form shou ldbe co mpleted and reported to Takeda 
Pharmacovigilance or designee within 24 hours to the attention ofthe con tact listed in Section 1.1.
Any SAE spontaneously reporte d to the invest igator fo llowing the AE co llection period should be 
reported to t he spo nsor if con sidered related to study  parti cipation.
Report ing of Serious PTEs w ill follow the proc edure described for SAEs.
10.2.3 Reporting of Abnormal Liver Function Tests
If asubject is noted to have ALT or AST elevate d >3 ×ULN on 2 consecut ive occasions ,the 
abnorm alityshoul d be recorded as an AE. I n addit ion, an LFT Increases eCRF must be co mpleted 
providing addit ional information on relevant recent history , risk factors, c linical signs and 
symptoms and results of any addit ional diagnosti c tests perfor med.
If a subject is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN fo r whi ch an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on
 10.2.2 . The investig ator m ust con tact the m edical m onitor for disc ussion of the 
relevan t subject details a nd possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease or medical history/concurrent m edical  conditions. Follow-up laborato ry 
tests as described in Sect ion
 9.1.17 must al so be performed. In addit ion, an LFT Increases eCRF 
must be complet ed and transmitted with the Takeda SAE fo rm(as per Section 10.2.2 ).
10.3 Follow -Up of S AEs
If informat ion not available at the time of the fir st report becom es available at a later date, the 
investigator should comp lete a fo llow-up SAE form  or provi de othe r written docum entati on and
fax it imme diately within 24 hours of receipt . Copies of an y relevant data from the hospi tal notes 
(eg, ECGs, labo ratory  tests, di scharge summary, postmortem results) should be sent to th e 
addressee, if requested.
All SAEs shoul d be followed up unt il reso lution or permanent outcom e ofthe event. The timelines 
and procedure for f ollow-up reports are the same as those f or the init ial report.
10.3.1 Safety Reporting to Investigators, IRBs or IECs, a nd Regulatory Authorities
The sponsor wil l be responsible for report ing all susp ected unexpected serious adverse react ions 
(SUSA Rs) and any oth erapplicable SAEs to regulatory  authori ties, including the European 
Medicines Agency (EMA), investigators and IR Bs or IECs, as applicable, in accordance with 
national regulat ions in the countr ies wh ere the stu dy is conducted. Relat ive to th e first awarene ss
of the event by /orfurther provisio n to the sponsor or sponsor’s designee, SUSARs will be 
submitted to the regulatory  authori ties as expedi ted report within 7 days for fatal and 
life-threate ning e vents and 1 5days for other serious events , unless otherw ise requi red by natio nal 
regul ations. Th e sponsor will also prepare an expedited report for other safet y issues w
here these 
might materially alter the cur rent benefit -risk assessmen t of a study drug/ sponsor sup plied drug or 
that woul d be suf ficient to cons ider changes in the s tudy drug/sponsor s upplied drug 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 63of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
administration or in the overall conduct of the trial. The s tudy site also will forward a copy  of all
expedited reports to his o r her IRB or IEC i n accordanc ewith local regulat ions.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 64of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
11.0 STUDY- SPECIFIC COMMI TTEES
No data safet y monitoring co mmitte e will be used in this study.
11.1 Steering Committee 
The Steering Co mmit tee will co mprise medical experts involved in th e study , the sponsor, an d an 
indepen dent s tatistician .The Steeri ng Co mmittee will r emain blinded t o treatm ent assignmen ts 
throughout the c onduct of the study. The Steering Committee will oversee the conduct and 
reporting of the study , ensuring expert c linical guidance and a high standard of scien tific quali ty, 
and making any necessary mo dificat ions to the protocol . The Ste ering Co mmit tee cha rter will  
define the responsibilit ies of the committee.
11.2 Adjudication Comm ittee
A PML Independent Adjudication Co mmittee (IAC) will be inst ituted for thi sstudy . The PML 
IAC will consist of a panel of l eading PML expe rts, including a neur ologist, neuroradio logist, and 
a viro logist. Adj udicati on will  be done on blinded data.
11.2.1 Risk Assessment and Minimization Action Plan forPML (RAMP) Program
Nata lizumab (TYS ABRI), another in tegrin receptor antagonist, has been associate d with PML, a 
rare an d often fatal oppor tunistic infection o f the central  nervous system . PML is caused by  the 
John Cunningham virus (JCV) and typically o nlyoccurs in subjects who are immunoco mpromi sed 
[
41, 42] . Nataliz umab is a pan -α4 integrin antagonist tha t binds to both the α4β1 an d α4β7 
integrins and inh ibits cellular adhesio n to VCAM -
1 and MAdCAM -1 [43, 44]. In contras t, 
vedo lizum ab bin ds to the α 4β7 i ntegrin only [21]and inhibits adhesio n to MAdCAM - 1, but not
VCAM -1. Al though no cases of PML have been reported in clinical tri als wi th vedolizum ab to 
date, a risk of PML cannot be ruled out.
To address the theoretical risk o f the development of PML in subjects treated with vedo lizumab, 
the sponsor, with input fro m renowned PML experts, has developed a Risk Minimization Act ion 
Plan for PML, t he RAM P. The com plete description of the RAMP program, including materials 
and instructions for its implementation and mo nitoring, is included in the Invest igator Sit eFile.
The RAMP is focused on early clinical detection and management of tha t specific s afety risk, 
inclu ding the di scont inuat ion of study  drug, if applicable. Subjects are assessed for signs and 
symptoms of PML prior to the administration of each dose o
fstudy  drug using a PML subject ive 
symptom  checklist. Subj ects wi th a posi tive PML subjec tive s ymptom chec klist at any  time after 
enrollment in a vedolizumab clinical study will be evaluated according to a prespecified algorithm 
(the PML Case Evaluat ion Algorithm).The next dose of study  drug will be held unt il the 
evaluat ion is co mplete and r esultsare availa ble. Subsequent doses of study  drug will  be 
administered only  if the possibilit y of PML is definit ively  excl uded, as described in the RAMP 
algorithm.An IAC ha s been established as part of the RAMP program to review new neuro logical 
signs and symptoms pote ntially consistent wi th PML, and will provide input regarding subject 
evaluat ion and m anagement as defined in the IAC charter.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 65of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
To ensure success of t he RAMP pr ogram , site personnel will be trained to recognize the features of 
PML, and subj ects w ill be trai ned to report specific neurological signs and symptoms without 
delay. Educati onal materi als for teaching site personnel and subjects about PML and th eRAMP 
procedures will be distributed to all sites and are included in the Inv estigator Si te Fil e. Formal  
teaching and training will be performed for site personnel prior to the start of the study. Subjects 
will receive training and educat ional materi als pr ior to re ceiving treatment. The informed consent 
form will contain specific i nformat ion on the hypotheti cal risk of PML. Any documented case of 
PML will be reported as an SAE, regardless of whether hospitalizat ion occurs.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 66of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
12.0 DATA HANDLING AND RE CORDKEEPING
The full de tails of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history , and concurrent m edical  condi tions will be coded using the Medical 
Dictionary for Regulatory  Activities (MedDRA). Drugs will be coded using the World Heal th 
Organizat ion Drug Di ctionary (WHODRUG) .
12.1 eCRFs 
Com pleted eCRFs are requi red for eac h subject who signs an informed consent.
The sponsor or its designee will supply study sites with access to eCRFs. The sponsor or delegated 
contract r esearch o rganization (CRO) will make arrangements to train appropriate site s taff in the 
use of the eCRF. These forms are used to transmit the informat ion collected in the performance o f 
this study  to the sponsor and regulatory  authori ties. eCRFs must be completed in English.
After complet ion of the entry process, computer logic ch ecks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answer ed by the site. 
Correcti ons to eCRFs are recorded in an audit trail that capt ures the old infor mation, the new 
inform ation, identificat ion of the person making the correction, the date the correction was made, 
and the reason for change.
The principal inv estigator must review the eCRFs for completeness and accuracy and must sign 
and date the a ppropr iate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
The p rincipal i nvest igator must review the data change for completeness and accurac y, and m ust 
sign, or sign and seal, and date.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by the sponsor or its designee. T he sponsor or its designee will be permitted to review the subject’s 
medical a nd hospital record s perti nent to the study  to ensure accuracy  of the eCRFs. The 
completed eCRFs are the sole property  of the sponsor and should not be made available in any 
form to third parties, except for authorized representatives o f appropri ate governm ental  healthor 
regulatory  authorities, wi thout wri tten permissio n of the sponsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific docum ents, the i dentificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
work sheets, al l original  signed and dated inform ed consent form s, subject authoriz ation forms 
regard ing the use of personal  health information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed reco rds of drug di sposi tion to 
enable evaluat ions or audits from regulatory  author ities, the s ponsor or its des ignees. Any  source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 67of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
and filed wit h the original in the s ubject’s c hart to ensure long -term legibilit y. Furthermore, 
International Conf erence on Ha rmonisation (ICH) E6 Secti on 4.9.5 requi res the investigator to 
retain essential documents specified in ICH E6 (Section 8) until at least 2 y ears after the last 
appro val of a market ing applicat ion for a specified drug indicat ion being invest igated or, if a n 
application is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time sp ecified by applica ble regulat ory requirements or for a 
time specified in the study  site agreem ent between the invest igator and sponsor.
Refer to the study  site agreement for the sponsor’s requi rements on record retention. The 
investigator should contact an d receive wr itten approval fr om the sponsor before disposing of any 
such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 68of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to database lock. This 
docum ent will provi de further details regar ding the de finition of analysis variables and analysis 
methodol ogy to address all study  objectives.
A blinded data review will be conducted prior to database lo ck. This r eview will assess the 
accuracy  and com pleteness of the study  databas e, subject e valuabilit y, and appropri ateness of the 
planned statistical methods.
13.1.1 Analysis Sets
All rando mized subjects will contribute to the full analysis set (FAS) and be used for the pr imary 
analysis population for efficacy . Subjects in the FAS will be analyzed acc ording to the tre atment 
they were randomized to receive.
All FAS subjects who do not have any  major protocol  violations will be included in the 
per-protocol (PP) popul ation. Ma jor protocol  violations will be specified in the SAP. 
All subjects who received at least 1 dose of study  drug will  be included in the safet y analysis set 
(SAF).
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Baseline and demographic informat ion will be listed and summarized. For continuous variables, 
the summ ary will consist o f descript ive stati stics (number of subjects, mean, standard deviat ion, 
minimum, median, and maximum). For categorical variables, the summary will consist of nu mber 
and p ercentage of subjects in each category .
Medical history and concurre nt medical c onditions will be summari zed by system organ class and 
preferred term. Medicat ion history  and conco mitant medicat ions will be summarized by preferred 
term.
13.1.3 Efficacy A nalysis
The primary  efficacy endpo int is the percentage of subjects who achie ve remissio n after 14 weeks 
of treatm ent (defined as a mPDAI score <5 and a reduction of overall score by  ≥2 points from 
Baseline). Subjects who withdraw early for any reasons wil l be included in the deno minator for the 
estimation of this percentage. At th e final analysis, the differ ence between the percentages of 
subjects achieving remissio n at Week 14 in each treatment group will be assessed by the 
chi-squared test. The null hypothesis, that the percentage of subjects achie ving remissio n at 
Week 14 in eac h treatment group is the sam e, will be tested against the alternat ive hypothesis that 
the 2percentages are not the same.
The secondary  endpoint, the time to symptomat ic remissio n (defined as a PDAI score <7 and a 
decrease in PDAI score of ≥3 points fro m Baseline), will be analyzed b y survival analysis 
procedures. Remis sion rates fro m the time o f randomizat ion over the 34 -week study  period will be 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 69 of 107Protocol Incorporating Amendment No. 04 14 September 2020
estimated by Kaplan-Meier product limit methods. The log-rank test will be applied to compare 
the 2 treatment groups. Cox proportional hazards regressi on will be performed to explore the effect 
of prognostic fact ors. Adjustments for baseline imbalances on key prognostic factors will be made 
using Cox regression. As this is a multi center clinical study, heterogeneity of tr eatment effect 
across the participating centers will be explored. 
Other dichotomous secondary endpoints will be analyzed by calculating rates and corresponding 
95% confidence intervals, which will be reported by treatment group; rate differences between treatment groups and their 95% confidence intervals will also be reported.
Change from baseline in mPDAI, PDAI,  IBDQ, and CGQL scores will be analyzed 
using Wilcoxon rank-sum tests; the Wilcoxon-Man n-Whitney odds estimator and its 95% CI will 
also be presented.
The primary efficacy analysis will be based on the FAS population including all randomized 
subjects. Analysis will also be performed on the PP population for confirmatory purposes.
Statistical tests will be 2-sided and pe rformed at the 0.05 level of significance.
13.1.4 Safety Analysis
Safety analyses will be based on the SAF set.  All subjects who received at least 1 dose of study 
drug will be included in the safety analysis set. No formal statistical tests or inference will be 
performed for safety analyses. Safety data will be presented by treatment group.
The number and percentage of subjects with AEs (regardless of relationship to study drug), AEs of 
special interest (ie, serious infections including opportunistic infection such as PML, liver injury, 
malignancies, infusion-related or systemic reactions, and hypersensitivity), AEs leading to 
discontinuation, and SAEs that occur on or after the first dose date and up to 18 weeks after the last 
dose date of the study drug will be summarized by MedDRA system organ class, high level term, 
and preferred term overall, by severity, and by relationship to study drug. If a subject experienced 
more than 1 AE for a given preferred term, intensity is defined as the intensity of the most severe 
event and relationship to study drug is the relationship of the most related event. 
Change from Baseline in clinical laboratory tests, vital signs and weight will be summarized by 
treatment group. Subjects with markedl y abnormal va lues for laboratory tests and vital signs will 
be tabulated.
Physical examination findings and PML checklist data will be presented in data listings.
Data from the long-term follow-up survey will be summarized descriptively.
13.2 Futility Analysis and Criteria for Early Termination
A single futility analysis will be performed when 25 patients per tr eatment arm have been recruited 
and completed their Week 14 assessment of primary efficacy. The purpose of this analysis will be 
to assess futility, and at this point simu lations will be performed to determine the posterior 
probability of achieving a treatment difference of at least 2 5% between the active and placebo 
treatment arms. On the basis of the posterior probability of success, a decision will be made to CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usede e 
espondispond
es betwes be
will be ill be
tor and or and
inclncludiudll
or confir conf
elel of ofl sig sff
ubjects bject
No formo for
llbe be pr
with AEsith AE
includinncludi
ystemic stemic
ccur cur ono
ill be sull be s
 bybysevesevyy
ven preen pr
p to stu to stu
selielinenin
up. Subjp. Sub
d..
al examexam
ta froa fro m
13.213.2
A
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 70of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
continue or terminate the study on the grounds of futilit y or to continue the study to com pletion. It 
is not intended to stop the stu dyon the grounds of efficacy; hence, no adjust ment to the statist ical 
significance l evel used for testing at the final analysis is necessary .
13.3 Determination of Sample Size
The sample size is calcul ated base d on the remission rate at 14 weeks. The p revious s
ample size 
was based on the ob served remissio n rate in GEMINI 1 in patients with moderate to severe 
ulcerat ive co litis: the placebo group remissio n rate was 8%, the vedo lizumab group rate was 23%;
an effec t size of  15%. 
However , pouchi tis is diff erent fr omUC and a new assessment using published data was made to 
evaluate what would be a significant treatment effect. On the basis of 2 recent papers using the 
mPDAI as the primary endpo int [45, 46] , a placebo rate of 15% was estimated. A clinical ly
significant effect was estimated to be of 25% , an aver age of the remissio n (complete response)
observe d inthe 2 aforem entioned paper s (32% and 21% post -induction response, respectively) 
evaluat ing the effect of infliximab using the mPDAI.
An effect size of at least 25% would be considered clinically meaningf ul (ie, a remissio n rate of 
40% in subje cts main tained on vedolizumab IV). Ther efore, a total of 98 evaluable subjects (49 per 
treatm ent group) will be required to detect a 25% difference in the remission rate at the 2 -sided 
0.05 l evel of signific ance wi th80% power. To account for attri tion, 11 0 subjec t
s will be 
rando mized (55 per t reatm ent group). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 71of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure tha t all 
aspects of the pr otocol  are f ollowed. Sour ce documents will be reviewed f or verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source docum ents by the spons or or i ts 
designe e (CRO) andby the IRB or IEC.
All aspe cts of the study and its documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the I nvest igator’s Binder, 
study  drug , subject medical records , info rmed consent docum entati on, docum entati on of  subject 
authori zation to use personal healt h information (if separate from the informed consent forms), 
and review of eCRFs and associated source do cuments. It is important that th e invest igator an d 
other s
tudy personnel are available during the mo nitoring visit s and that sufficient time is devoted 
to the process.
14.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary to eliminate an 
immedi ate hazard to stu dysubje c
ts.Should other unexpected ci rcumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as requi red) to d etermine the appropriate course of actio n.There will be 
no exempt ions (prospec tively approved deviations) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event o f 
a significant deviat ion, the s ite shoul d notify the spo nsor or its desi gnee (and IRB o r IEC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confoun d interpr etation of  primary  stud y 
assessment. A P rotocol  Devi ation Form  should be comple ted by  the site and signed by the sponsor 
or desi gnee for any  significant deviat ion from the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The st udy site 
also m ay be subject to qualit y assurance audits by the sponsor or designees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where labo ratory  samples are co llected, 
where the m edicati on is sto r
edand prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments ( eg, the F ood and Drug Administra tion [FDA], the Uni ted Ki ngdo m 
Medicines and Healt hcare products Regulatory Agency, the Pharmaceut icals and Medical Devices 
Agency o f Japan). If the study site is contacted for an inspect ion by a regulatory body, the sponsor
shoul d be notified immediately. The invest igator and ins t
itution guarantee access for q uality 
assurance auditors to all study  docum ents as described in Sect ion 14.1.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 72of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be condu cted wi th the highest r espect for the in dividual participants (i e, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investi gator wil l conduct 
the study  according to applica ble local orregional regulatory requir ements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The princi ples of Helsinki are addressed through t heproto coland through appendices cont aining 
requi rements for informed consent and invest igator responsibilit
ies.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and feder al/local requirements 
of each participat ing regi on.The sponsor or designee wil l require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this s tudy, written notification regar ding his or her a bstinenc e from 
voting must also be obta ined. Those Americas sites unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable nu mber assigned by  the Departme nt of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Inve stigator’ s Brochure, the 
vedo lizumab IV (Entyvio) package i ns ert, a copy of the informed consent form, and, if applicable, 
subject recruitment materials and/or advertisements and other documents required by all 
applicable laws and regulations, must be subm itted to a central or local IRB or IEC for approv al. 
The IRB’ s or IEC’s written approval of the protocol and subject informed consent must be 
obtained and submitted to the sponsor or designee before commencement of the study  (ie, before 
shipment of the spo nsor-supp lied drug or study spec ific screening ac tivity). The IRB or IEC 
approval  must refer to the study by exact protocol title, number, and versio n date; ident ify versio ns 
of other documents (eg, informed consent form) reviewed; and state the approval d ate. The 
sponsor will notify  site once the sponso r has co nfirmed the adequacy  of site regulatory  
docum entati on and, when applicable, the sponsor has received permissio n from competent 
authori ty to begin the tri al. Unt il the site receives notification no pr otocol  activities, including 
screening m ay occur.
Study si
tesmust adhere to all require ments st ipulated by their respect ive IRB or IEC. This may 
include notificat ion to the IRB or IEC regarding protocol amendments, updates to the informed 
consent form, re cruitmentmaterials intended for viewing by subje cts, local safety reporting 
requi rement s, reports and updates regarding the ongoing review of the study at intervals specified 
by the respect ive IRB or IEC, and submission o f the invest igator’s final status report to IRB or 
IEC. All IRB an d IEC approvals a ndrelev antdocumentation for these ite ms must be provided to 
the sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IE C and sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 73of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
15.2 Subject Information, Info rmed Con sent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accord ance wi thall 
applicable laws an d regulati ons. Th e inform ed consent form , subject author ization form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s persona l and per sonal healt h informat ion for purposes of
conduct ingthe study . The informed con sent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date inform ed consent i s given. Th e inform ed consen t form willdetail  the requi rements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the pr eparati on, conten t,and I RB or IEC approval of the 
infor med consent form and if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if appl icable) must 
be approve d by both the IRB or IEC a
ndthe sponsor pri or to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible t o the pro spective subject. 
It isthe responsibili tyof the invest igator to explain the d etailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information sho uld be gi ven in both oral and wr itten form  whenev erpossi bleand in the 
manner deemed ap propri ate by  the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representativ e may 
provide such consent for t he subject in acc ordance with applicable laws and regula tions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whethe r or not to participate in the s tudy. If the 
subject, or thesubject’s legally acceptabl e representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and d ated by  the subject, or the subj ect’s l egally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, no t nicknames, 
using blue or black ballpo intink. T
heinvest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering 
into the study; however, the sponsor may allow a designee of the inve stigator to sign tothe extent 
permitted by  applicable l aw.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the inv estigator ’s site file. The 
inves tigator m ust docu ment thedate the subject signs the inf ormed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet ( if applicable) shall be given to the sub ject.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 74of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
All revised informed consent form s must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained should be r ecorded in the subject’s medical 
record , and the subject should receive a copy o f the revised informed consent form.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the s ubject’s right to protection 
against invasio n of privacy. Throughout this study , a subje ct’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws a nd regula tions, limited subject attributes, such assex, age,or date 
of birth, and subj ect init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mplianc e with th is protocol, the sponso r 
requi res the in vestigato
r to permit its monitor or des ignee’s m onitor, representatives from  any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency ), the sp onsor’s designated audi tors, and the 
appropriate IRBs and IECs to review the su bject’s ori ginal  medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summari es for ho spital admissio ns occur ring during a subje ct’s s tudy partici pation, 
and autopsy reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section
 15.2).
Copi es of any s
ubject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the s ubject’s eCRF).
15.4 Publication, Dis closure, and Clin ical Tri a
l Registration Policy
15.4.1 Publicat ion and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the st udy, only the sponsor m ay make study  
information ava ilable to other study  investigators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure ( including publicly accessible we bsites) related t o the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (incl uding dat a and informatio n 
gener ated by  the inves tigator) w
ithout the consent of the inv estigator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and pr esentati ons must be pre pared in accordan cewith 
thissection and the clinical s tudy site agreement. In the event of any discrepancy between the 
protocol  and the clinical study  site agreement, the clinical study  site agreement will  prevail.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 75of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
15.4.2 Clinica l Trial Registration
In order to ensure that info rmation on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register 
intervent ional clinical tri als it sponsors an ywhere in the worl d on ClinicalT rials.gov and/or other 
public ly accessible websites befo re start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along with invest igator’s cit y, state (for American investigators), country, and 
recruiting status will be register ed and available for publ i
c viewing. 
For some registrie s, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing tri al 
inform ation. Once subjects re ceive invest igato r contac
t info rmation, they  may call  the site 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening proce ss. If th e caller asks addit ional 
questions bey ond the topicof trial enrollment, they s hould be referred to the sponsor. 
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice requ esting th at thei r inform ation 
not be listed on th e regist ry site. 
15.4.3 Clinical Trial Result s Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov and/or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable l aws and/or regulat ions.
15.5 Insurance and Co mpensati on for Injury
Each subject in t he study must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the spon sor or sp onsor’s 
designee will o btain clinical st udy insur
ance against the ri sk of  injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has question s regardi ng this policy, he or s he should contact the spo nsor
or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 76of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
16.0 REF ERENCES
1. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery  IC, Milso m JW, et al. Ileal pouch -anal 
anastom oses com plicat ions and function in 1005 patients. Ann Surg 1995;222(2):120 -7.
2. Ferrante M, Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, et al. 
Outcom e after proctocol ectomy  with ileal pouch -anal anastom osis for ul cerative colit is. 
Inflamm Bowel Dis 2008;14 (1):20 -8.
3. Shen B. Acute and chronic pouchit is--pathogenesis, diagnosis and tre atment. Nat Rev 
Gastroenterol H epatol  2012;9(6):323-33.
4. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high 
dose probi otic therapy  (VSL#3) for maintaining remissio n in recurrent or refractory  
pouchi tis. Gut 2004;53 (1):108 - 14.
5. Gionchetti  P, Ri zzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis 
of pouchi tis onset wi th probi otic therapy : a doubl e-blind, placebo -controlled trial. 
Gastroenterology  2003;124(5):1202-9.
6. Proni o A, Montesani C, Butt eroni C, Vecchio ne S, Mum olo G, Vestri  A, et al . Probi otic 
administration in pat ients with ileal pouch -anal anastom osis for ulcerative colit is is 
associ ated wi th expansio n of mucosal regulatory  cells. Inflamm  Bowel  Dis 
2008;14(5):662 -8.
7. Shen B, Brzezins kiA, Fazio VW, Remzi FH, Achka rJP, Bennett AE, et al. Maintenance 
therapy  with a probi otic in ant ibiotic- dependent pouchit is: experience in clinical practice. 
Aliment Pharma col Ther 2005;22(8):721-8.
8. Mahadevan U, Sandborn WJ. Diagnosis and management o
fpouchi tis. Gastroenterology  
2003;124(6):1636 - 50.
9. Landy  J, Al -Hassi  HO, McLaughlin SD, Knight SC, Ciclit ira PJ, Ni cholls RJ, et al. 
Etiology of pouchi tis. Inflamm Bowel D is 2012;18(6):1146 -55.
10. Lovegrove RE, Tilney HS, Heriot AG, von Roon AC, Athan asiou T, Church J, et al. A 
comparison of adverse events and funct ional outcomes after restorative proctocolectomy 
for familial adeno matous polyposis and ulcerat ive colit is. D is Colon Rectum 
2006;49(9):1293 -
306.
11. Shen B, Lashner B. Can we immunogenoty pically and immunophenoty pically profile 
patients who are at risk for pouchit is? Am J Gastroenterol  2004;99(3):442 -
4.
12. Brett PM, Yasuda N, Yiannakou JY, Herbst F, Ellis HJ, V aughan R, et al. Genet ic and 
immuno logical markers in pouchit is. Eur J Gastroente rol Hepatol 1996;8(10):951-5.
13. Carter MJ, Di Gio vine FS, Cox A, Goodfellow P, Jones S, Shorthouse AJ, et al. The 
interleukin 1 receptor antagonist gene allele 2 as a predic tor of  pouchi tis following 
colectomy and IPAA in ulcerat ive co litis. Gastroentero l
ogy 2001;121(4):805-11.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 77of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
14. Meier CB, Hegazi RA, Aisenberg J, Legnani PE, Nilubo l N, Cobrin GM, et al. Innate 
immune receptor genetic polymorphisms in pouchitis: is CARD15 a suscept ibility factor? 
Inflamm Bowel Dis 2005;11(11):965 -71.
15. Sehgal R, Berg A ,Hegarty  JP, Kelly  AA, Lin Z, Poritz LS, et al . NOD2/CARD15 
mutati ons correl ate wi th severe pouchit is after ileal pouch -anal anastom osis. Dis Col on 
Rectum 2010;53(11):1487 -94.
16. Herfarth HH, Long MD, Isaacs KL. Use of Bio logics in Pouchitis: A Systemati cReview. J 
Clin Gastroenterol 2015;49(8):647 - 54.
17. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocy te trafficking and 
regional immuni ty. Adv Immunol  1999;72: 209-53.
18. Salmi M, Jalkanen S. Lymphocy te homing to the gut: attraction, adhesi o
n, and 
commit ment. Immuno l Rev2005;206:100 -13.
19. Briskin M, Winsor -Hines D, Shyjan A, Cochran N, Bloom S, Wilso n J, et al. Human 
mucosal addressin cell adhesio n molecule -1is preferent ially expressed in intestinal tract 
and associated lympho id tissue. AmJ Pathol  1997;151(1):97 -110.
20. Erle DJ, Briskin MJ, Butcher EC, Garcia -Pardo A, Lazarovits AI, Tidswell M. Expressio n 
and function of the MAdCAM -1 receptor, integrin alph a 4 beta 7, on human leukocy tes. 
Immuno 1994;153(2):517-28.
21. Soler D, Chapman T,Yang LL, Wyant T, Egan R, Fe dyk ER. The bi nding specificit y and 
select ive antagonism o f vedo lizumab, an ant i-alpha4beta7 integrin therapeutic ant ibody  in 
development for inflammatory  bowel  diseases. J Pharmaco l Exp Ther 
2009;330(3):864 -75.
22. Hurst RD, Chung TP, Rubin M, Michelassi F. The implica tions of acute pouchit is on the 
long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis 
1998;4(4):280 -4.
23. Madiba TE, Bartolo DC. Pouchit is following restorative proctocolectomy for u lcerative 
colitis: incidence and therapeuti c outcom e. J R Coll Surg Edinb 2001;46(6):334 -7.
24. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment 
of ulcerat ive co litis with a humanized ant ibody  to the alpha4beta7 integrin. NEngl J Med 
2005;352(24):2499 -507.
25. Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long -term clinical  experience 
with vedolizumab in patients with inflammatory  bowel  disease. Inflamm Bowel Dis 
2013;19(8):1691 -
9.
26. Feagan BG, Greenberg GR ,Wild G, Fedorak RN, Pare P, M cDonal d JW, et al. Treatment 
of active Crohn's disease wit h MLN0002, a humanized ant ibody  to the al pha4beta7 
integrin. Clin Gastroenterol Hepatol 2008;6(12):1370-7.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 78of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
27. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colo mbel JF ,Sandborn WJ, et al. 
Vedolizum ab as induct ion and maintenance therapy for ulcerative co litis. N Engl J Med 
2013;369(8):699 -710.
28. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colo mbel JF, Sands BE, et al. 
Vedolizumab as induct ion and maintenance ther apy for Crohn's disease. N Engl J Med 
2013;36 9(8):711 -
21.
29. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch -anal 
anastom osis for chronic ul cerat ive co litis: complications and long- term outcom e in 1310 
patients. Br J Surg 1998;85(6) :800-3.
30. Shen B, Lashner BA. Diagnosis and treatm ent of pouchit is. Gastroenterol Hepatol (N Y) 
2008;4(5):355 -61.
31. Entyvio (vedo lizumab) for inject ion, for intravenous use .Full Prescribing Informat ion. 
Deerfield, IL: T akeda Pharmaceut icals America, I nc.,Issued M ay 2014.
32. Entyv io (vedo lizumab) 300 mg powder for concentrate for solut ion for infusio n. Summar y 
of Product Characterist ics. Denmark: Takeda Pharma A/S ,Issued 25 September 2015.
33. Sandborn WJ, Tremaine WJ, B atts KP, Pemberton JH, Phillip sSF. Pouchi tis after ileal 
pouc
h-anal anastomosis: a Pouchit is Disease Act ivity Index. May o Clin Proc 
1994;69(5):409 -15.
34. Shen B, Achkar JP, Connor JT, Ormsby AH, Remzi FH, Bevins CL, et al. Modified 
pouchi tis disease act ivity index: a simplified appro ach to the di agnosis of pouchit is. Di s 
Colon Rectum  2003;46(6):748 -53.
35. Daperno M, D'Haens G, Van Assche G, Baert F, Bulo is P, Maunoury V, et al. 
Development and validation o f a new, simplified endoscopic activit y score for Crohn's 
disease: the SES -CD. Gastrointest E ndosc 2004;60(4): 505-12.
36. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, et al. Reproducibilit y 
of histol ogical assessments of di sease activit y in UC. Gut 2015;64(11):1765 -73.
37. Irvine EJ. Dev elopment and subsequent refine ment of the in flammatory  bowel  disease 
questionnaire: a qualit y-of-life instrument for adult patients with inflammatory bowel 
disease. J Pedi atr Gastroenterol  Nutr 1999;28(4):S23 -7.
38. Guyatt G, Mi tchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new m easure 
of heal th status for clinical trials in inflammatory  bowel  disease. Gastroenterology  
1989;96(3):804 -10.
39. Guyatt GH, Dey o RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validit y 
in health status measurement: a clarification. JClin Epi demi ol 1989;42(5):403 -8.
40. Fazio VW, O'Riordain MG, Lavery  IC, Church JM, Lau P, Strong SA, et al. Long -term 
funct ional outcome and qualit y of life after stapled restorative proctocolectomy. Ann Surg 
1999;230(4):57 5-84; di scussio n 84- 6.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 79of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
41. MajorEO. Progres sive mult ifocal l eukoencephal opathy  in pat ients on immuno modulatory 
therapi es. Annu Rev Med 2010;61:35 -47.
42. Steiner I, Berger JR. Update on progressive mult ifocal  leukoencephalopathy . Curr Neurol  
Neurosci Rep 2012;12(6):680 -6.
43. Sandborn WJ, Col ombel JF, Enns R, Feaga nBG, Hanauer SB, Lawrance IC, et al. 
Natalizumab induct ion and maintenance therapy  for Crohn's di sease. N Engl  J Med 
2005;353(18):1912 -25.
44. TYSABRI (natalizumab) inject ion. Full Prescribing Informat ion. Cambridg e, MA: Bio gen 
Idec Inc. ,Revised Ma y 2015.
45. Ferrante M, D'Haens G, Dewit O, Baert F, Holvoet J, Geboes K, et al. Efficacy o f 
infliximab in refractory  pouchi tis and Crohn's disease -related com plicat ions of the pouch: 
a Bel gian case series. Inflammatory  Bowel  Disea s
e2010;16(2):243 -9.
46. Barrei ro-de Acosta M, Garcia -Bosch O, Souto R, Manosa M, Miranda J, Garcia -Sanchez 
V, et al. Efficacy o f infliximab rescue therapy in patients with chronic refractory pouchit is: 
a multicenter study . Inflammatory  bowel  diseases 2012 ;18(5):812 - 7.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 80of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix ASchedu le of Study P rocedures
Screening TreatmentFinal 
Endosc
opy 
Visit
or ETSafety 
Follow -Up
(a) Post- Study
Study Day/Week:Days
-28 to -1Wk0/ 
Day 1Wk 
2Wk 
4Wk 
6Wk 
14Wk 
22Wk 30 
(EOT)Wk 34
(EOS)Wk 48
(or 18 
weeks 
p o st-tx if 
ET)Phone Wk 
56
(or 26 
weeks 
post-tx if 
ET)
Visit Windows (D ays): ±2 ±2 ±2 ±3 ±7 ±7 ±7 ±7 ±7
Visit Number: 1 (b) 2 3 4 5 6 7 89 (c) 
/ET 10 11
Informed Consent (d) X
Inclusion/Exclusion Criteria X X
Demographics X
Medical/Surgical History X (e)
UC/Pouchitis Disease 
HistoryX
Concomita nt
Medications/Procedures (f)X X X X X X X X X X
Physical Exam X X X X X X X X X
Weight & Height X (g) X X X X X X X X
Vital Signs X X X X X X X X X
ECG X
IBDQ X X X X
CGQL X X X X
mPDAI X(h) X X
PDAI X (h)(i) X X
Pouch Endoscopy with 
Biops yX X X
Hematology X X X X X
Serum Chemistry and Other 
Laboratory TestsX X X X X
HIV/He patitis panel X (j)
Urinalysis X X X X X
CRP X X X X X
FSH (k) X
Tuberculosis 
QuantiFERON or Skin T estX
C difficile test X
Serum Pregnancy Test (l) X X
Urine Pregnancy Test (l) X (m) X (m) X X (m) X (m) X (m) X (m) X
Fecal Calprotectin Assay X X (m) X X X X
Study  Drug Dosin g(IV) (n) X X X X X X
Ciproflox acin X X X (o) X(o) X(o) X(o)
Footnotes are on last table page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 81of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix A Schedul eof Study Proce dures (contin ued)
Scree ning TreatmentFinal 
Endosc
opy 
Visit 
or ETSafety 
Follow -Up 
(a) Post- Study
Study Day/ Week:Days
-28 to -1Wk0/ 
Day 1Wk 
2Wk 
4Wk 
6Wk 
14Wk 
22Wk 30 
(EOT)Wk 34
(EOS)Wk 48
(or 18 
weeks 
post-tx if 
ET)Phone Wk 
56
(or 26 
w
eeks 
post-tx if 
ET)
Visit Win dows (Days): ±2 ±2 ±2 ±3 ±7 ±7 ±7 ±7 ±7
Visit N umber: 1 (a) 2 3 4 5 6 7 89 (b) 
/ET 10 11
PML Checklist X X (m )X (m) X X (m) X (m )X (m) X (m) X X
Provide PML Wallet C ard X X
PTE Assessment (f) X X
AE/SAE Assessment (f ) X X X X X X X X X
Long -Term Follow -Up 
QuestionnaireX
Access IWRS to Obtain 
Subje ct IDX
Access IWRS for 
RandomizationX
Access IWRS to Register 
VisitX X X X X X X X
Wk=Week.
(a) If subject is m ale or subject is p ostmenopaus al and cannot attend the site for the safety follo w-up visit, the safety 
follow -up vis it may be conducted via pho ne.
(b) Onc e informed consent is obtained, listed procedures may be performed at any time during the sc reening pe riod.
(c) Perform V isit9 proc edures if subject withdraws before Week 34.
(d) In formed consent process can begin pri or toVisit 1, for example, ifwashout from medi cations is required. 
(e) Smoking/nicot ine usage status will be captured as part o fmedical histor y.
(f) Record a
dverse ev ents, PTEs, and medications from the time of signi ng the Informed Consent Form. 
(g) H eightcollected only at Vis it 1.
(h) C linical mP DAI and PDAI scores (patient reported s ymptoms) will be assessed as average from 3 days imme diately prior to 
baseline endo scopy (or bowel preparation for endoscopy). Recording will be facilitated by a paper di ary.
(i) Clinical and endo scopic PDAI scores fo r Visit 2 will be the scores obtained during Screening, and the histologic score w ill be 
added whe n available t o complete the full PDAI score.
(j) Hepatitis and HIV testing only done at the Screening Visit.
(k) On ly if menopause is sus pected.
(l)Only requ ired for women of child bearing potenti al.
(m) To be performed before dosing.
(n) Subjects s hould be observed f or2hours following the first 2 infusions, at a minimum, and 1 hour after each subsequent infusi on 
for monitoring hypersens itivity rea ctions.
(o) All subjects will receive ciprofloxac in 500 mg twice daily through Week 4. Addit ional anti biotics will be all owed, as ne eded, 
for flares after Week 14.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 82of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix BResponsibili ties of the Investigator
Clinical rese arch studi es sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local la wsand reg ulations. The respo nsibilit iesimposed on Invest igators fro m the FDA are 
summari zed in the “Statem ent of Invest igato r” (Form FDA 1572) which mu st be compl eted and 
signed before the Invest igator may parti cipate in this study .
The invest igator agre
esto assu me the following re sponsibilit ies:
1.Conduct the study  in accordance wit h the prot ocol.
2.Personally conduct or supervis ethestaff who will assist inthe pro tocol .
3.Ensure that study  related procedures, incl uding study  specific (nonrouti ne/nonstandar dpanel ) 
screeni ng assessment s are NOT p erform ed on potent ial subjects, prior to the recei pt of written 
approval  from relevant gove rning bodies/authorit ies.
4.Ensure that all c olleagues and emplo yees assist ing in th e conduct of the study  are informed of 
theseobligat ions.
5. S ecure prior a pproval of the study  and any  changes by  an appropri ate IRB/ Secure pri or 
approval  of the study  and any changes by  an appropri ateIRB/IEC that conf orm to 21 Code of 
Federal Regulat ions (CFR) Part 56, ICH, and local regulatory  requirements.
6.Ensur e that the IRB/IEC will be responsible for init ial review, continuing revi ew, and approva l 
of the protocol. Pr omptly report to the IRB/IE C all chang es in rese arch act ivity and all 
anticipated risks to subjects. Make at least y early reports onthe pro gress of the study  tothe 
IRB/ IEC, and issue a final report within 3 months of s tudy com pletion.
7.Ensure that require ments for informed consent, asoutline d in 21 CF R Part 50, ICH and local 
regul ations, are met.
8.Obtain valid informed consent from e
ach subje ct who participates inthe stu dy, and docum ent 
the date of consent in the subjec t’s medical chart. Valid informed co nsent is the most current 
version appr oved by th e IRB/IEC. Each informed consent form s hould contain a subject 
authori zation sect ionthat de scribe s the uses an d disclosures of a subject’s personal 
inform ation (including personal healt h informat ion) that wi ll take place in connect ionwith the 
study. If an informed consent form does not includ e such a subject authorization, then the 
investigator must obtain a sepa rat esubjec t authorizati on form from each subject or the 
subject’s l egally acceptable representat ive.
9.Prepare and maintain a dequate cas e histori es of all persons entered into the study , incl uding 
eCRFs, hospital records, labora tory resul ts, etc, and mainta inthese da ta for a minimum o f 
2years fo llowing notificat ionby the sponsor that all invest igati
ons have been discont inued or 
that the regul atory authori ty has approved the marketing applicat ion. The invest igator should 
contac tand rece ive wr itten approva l from the sponsor before disposing o f any such 
docum ents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 83of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
10.Allow possible inspection and copying by th e regulatory  authori tyofGCP -spe cified ess ential 
docum ents.
11.Maintain current reco rds of the receipt, administratio n, and dis position ofspon sor-supplied 
dr
ugs, and return all unused sponsor -supplied drugs to the sp onsor.
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, no tify the sponsor 
within 24 hours.
13.If the invest igator/institution retains the serv ices of an yindividual  or par tyto perfo rm 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that thisindividual 
or party  is qualified to perfor m those tri al-related duti es and funct ions and shoul d implement 
procedures to ensure the integrityof the tri al-related du ties and funct ions performed and any 
data generate d.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 84of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix CElements of the Su bject Infor med Consen t 
In seeking informed consent, the fo llowing information shall be provided to eac hsubject:
1.A sta tement that t hestudy involves research.
2.An explanat ion of the purposes of the research.
3.
The expected duration of the subject’s participa tion.
4.A des cript ion of the procedures to be fo llowed, includ ing invasive procedures.
5.The i dentificat ion of any procedur es that are e xperimental .
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject ’s responsibilit ies.
8.A desc ription of  the conduc t of the study .
9.A statement describing the treatm ent(s) and the probabilit y for ran
dom assig nment to each 
treatmen
t.
10.A des cript ion of the possible side effects of the treat ment that the subject may  receive.
11. A descri ption of any  reasona blyforesee able ri sksor discomf orts to the subject and, whe n 
applicable, to an embry o, fetus, or nursi nginfant.
12.A des cript ion of a ny benefi tsto the subject or to others that reasonably  may be expected fro m 
the research. When t here is no intended clinica l benefi t to the subj ect, the subject should be 
made aware o f this.
13.Disclosures o f appropriate alternat ive proced ures o r courses of tre atment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefi ts.
14.A statement desc ribing t he extent to which confident iality of records i dentifying the subject 
will be maintained, an da note o fthe possibilit y thatregulat ory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written informed consent form, the 
subject or the subject’s legally acceptable repre sentative is authorizing such access.
15.For research in volving more than m inimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are avail able if inj ury occurs and, if 
so, what they  consist of or wh ere further informat ion may be obtained.
16.Theanticipated pr orated paymen t(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , tothe subject for participat ingin the study .
18.An explanat ion of whom to contact for answ ers to pertinent questions about the resear ch
(invest igator ), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statem ent that participa tion is vo luntary , that refusal to participate will invo lve no penalt y or 
loss of benefits to which the subject o therwi se is entit led, and that the subject may discont inue 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 85of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
participat ion at any  time wit hout penalt y or loss of bene fits to whi ch the subject i s oth erwise
entitled.
20.The consequences of a subject’s decisi on to wi thdraw from  the research and proced ures for 
o
rderly terminat ion ofparticipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be inf ormed 
in a timely  manner if informat ion beco mes available th at may be rel evant to the subject’s 
willing n
ess to co ntinue participat ion inthe study.
22.A statement that results of pharmacogenomic a nalysis will not be disclosed to an i ndividual, 
unless prevaili ng laws req uire the s ponsor to do so.
23.The foreseeable circum stances or reasons under which the subject’ sparticipation in the study  
maybe term inated.
24.A wr itten subject authorization (eit her co ntained within the informed consent form or provided 
as a separ atedocumen t) describ ing to the subject the contemplated and permissible uses and 
disclosures of the su bject’s pe rsonal information (in cluding personal health informat ion) for 
purposes of condu cting the study. The subject authori zation must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that person a
linforma tion (including per sonal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and s afety repor ting 
purpo ses, including, without limitat ion, to the following: (1) Takeda, its affiliates, and 
licens ing pa rtners; (2) b usiness par tners assist ing Takeda, its affiliates, and licens ing 
partners; (3) regulatory  agencie sandother healt h authorit ies; and (4 )IRBs/IEC s;
b)it is possible that personal informa tion (including personal healt h informat ion
)may be 
process ed and transf err ed to co untries that do not have data protection laws that offer 
subjects the same level o f protect ion as the data protec tion laws w ithin this country; 
however, Takeda will make eve ry effort to keep y our personal  information
confident ial, 
and your name willnot be disclosed outsi de the clinic unless required by l aw;
c)that personal information (inclu ding personal healt h inform ation) m ay be added t o 
Takeda’s research databases for purposes of developing a better understanding of the 
safet yand effect iveness ofthe stu dy drug(s), studying other therapies for patients,
developing a better understanding o fdisease, and improving th e efficienc y of futur e 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their pers onal informat ion 
(including pe rsonal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restr icted use or disclosure of such inform ation may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity w
ill remain confi dential in the event tha t study  resul ts are 
published.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 86of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
25.Female subjects of childbearing potential (eg, nonsteri lized, premenopausal female subjects) 
who are se xually  active m ust use highly  effect ivecontracepti on (as defined in the informed 
consent) f rom Screening throughou t the d uration of the study. Regular pregnancy tests will be 
perform ed throughout the study f or all female subjects of c hildbearing potenti al. If a subject is 
found to be pregnant during study , study  drug will  be discont inue
dand the inves tigator will 
offer the s ubject the cho ice to receive unblinded treatment i nform ation.
26.Male subjects must use h ighly effect ive contracepti on (as defi ned in the informed consent) 
from signing the inf ormed consent throughout the duration of th estudy . Ifthe partner or wi fe
of the subject is found to be pregnant during the study, the invest igator will offer the subje ct the 
choice to receive un blinded tre atment information.
27.A statem ent that clinical tri al informat ion fro m this trial will be publ icly discl osed in a publicly 
accessible websi te, such as ClinicalTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 87of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix DInvesti gator Consent to Use of Per sonal Infor mation
Takeda will co llect and retain personal i nformation of  invest igator, including his o rher name ,
address, and othe r personall y identifiable informat ion. In addit ion, invest igator’s personal  
inform ation may be transferred to other parties located in countri es throughout the world (eg, the 
United Ki ngdom , Uni ted States, and Japan), including t he following:
Takeda, its a ffiliates, and licensing partners.
Business partners assist ing Takeda, i ts affiliates, and licens ing partners.
Regulatory  agencies and other heal th authori ties.
IRBs and IECs.
Invest igator’s personal  inform ation may be retained ,processe d, and transferred by Takeda a nd 
these other parties for research purposes inclu ding the foll owing:
Assessment of th esuitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the st udy.
Analy sis, review, and ve rif
ication of the study  results.
Safety reporti ng and pharmac ovigilance relat ing to the study .
Preparation and submissio n ofregulatory filings, correspondence, and communicat ions to 
regulatory  agencies rel ating to the study .
Preparati onand s ubmissi on of regulatory filings, correspondence, and communicat ions to 
regulatory  agencies relat ing to other m edications used in other cl inical stud ies that m ay contain 
the sam e chemical com pound p resent in the study  drug.
Inspect ions and i nvest igati o ns by regul atory  authorities relating to the study.
Self-inspect ion and interna l audit within Takeda, i ts affiliate s, and licensing partners.
Archiving a nd audit o f study  records.
Posting invest igator s ite contact informat ion, study details and results on publi cly accessibl e 
clinical trial registri es, databases, and websites.
Invest igator’s personal  inform ation may be transferred to other countr iesthat do not have data 
protecti on laws that offer the sam e level of protection as data protection la wsin inve stigator’s own 
coun try.
Invest igator acknowledges and consents to the use of his or her personal  information by  Take da 
and other parti es for th e purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 88of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix EThe Pouchitis Disease Activity In dex (PDAI)
The P ouchitis Dise aseActivit y Index (PDAI) [33]
Criteria Score Subtotal
Clini cal Stool freque ncy
Usual pos toperative stool frequency
1-2 stools/day > postoperative usual
3 or mo re stools/day > postoperat ive usual
Rectal bleeding
N
oneor rare
Present d aily
Fecal urgency or abdominal cramps
None
Occasional
Usual
Fever (temperature >37.8 ◦C)
Absent 
Present0
1
2
0
1
0
1
2
0
1
Endoscopic inflammation Edema
Granularit y
Friability
Loss of vascular pattern
Mucus exudates
Ulceration1
1
1
1
1
1
Acute histologic 
inflammationPolymorphic nuc lear leukocyte infiltr ation 
None
Mild
Mode rate +crypt abscess
Severe + crypt abscess
Ulceration per low power field (mean)
0%
<25%
25-50%
>
50%0
1
2
3
0
1
2
3
Total PDAI
Based on Sandborn et al. Mayo Clin Proc. 1994; 69(5);409 -15.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 89of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendix FThe Modi fied Pouchitis Disease Activity Index (mPDAI) 
The Modified Po uchitis Disease Activity Index (mPDAI)
Criteria Score Subtotal
Clinical Stool frequency
Usual postoperative s tool frequency
1-2 stools/day > postoperativ e usual
3 or mo re stools/day > postoper ativeus
ual
Rectal ble eding
None or ra re
Present daily
Fecal u rgency or abdominal cramps
None
Occasional
Usual
Fever (temperature >37.8 ◦C)
Absent 
Present0
1
2
0
1
0
1
2
0
1
Endoscopic inflammation Edema
Granularity
Friability
Loss of vascular patt ern
Mucu s exudates
Ulceration1
1
1
1
1
1
Total mPDAI
Based on Shen et al. Dis Colon Rectum 2003:46(6):748 -53[34]. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 90 of 107Protocol Incorporating Amendment No. 04 14 September 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usemercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 91 of 107Protocol Incorporating Amendment No. 04 14 September 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 92of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Appendi x I Inflammatory Bowel D isease Questionnaire (IBD Q)
INSTRUCTIONS FOR SELF -ADMINISTERED IBDQ
This qu estionnaire is designed to measure the eff ects of your inflammatory  bowel disease on your 
daily  function and qualit y of life. You will be asked abo ut symptoms y ou have been h aving a s a 
resul t of your bowel  diseas e,the way  you have been feeling in general, and how y our m ood has 
been.
On this quest ionnaire there are 32 questions. Each question has a graded response numbered fro m 
I through 7. Please re ad each question carefully and ci rcle/mark the number which best describes 
how y ou have been feeling in the pas t 2 weeks.
EXAMPLE
How often have you fe lt un well as a result of your bo wel problem in the past 2 we eks?
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF T HE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Ifyou are having trouble understanding a quest ion,STOP for a m oment! Thi nk about what the 
question m eans to y ou. How is i t affected by  your bowel probl em? Then answer the q uestionas 
best you can. You wil l have the chance to ask the research assistant ques tions after complet ing the 
questionnaire . Thi s takes only a few minutes to complete.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 93of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE 
(IBDQ)
This questionnaire i s desig ned to find out how you h ave be en feeling during the last 2 weeks. 
You will be asked about symptoms you have been hav ing a s a result of your inflamma tory 
bowel disease, the way you have been feeling i n general, and how you r mood has been.
1.How freque nt have your bowel  movements bee n duri ng the last two weeks? Please indicate 
how f requent y our bowel  movements have been dur ing the last two weeks by  pickin g one of 
the opti ons from
1 BOWEL MOVEMENTS AS OR M ORE FREQUENT THAN THEY HAVE EVER 
BEEN
2 EXTREMELY FREQUE NT
3 VERY FREQUENT
4 MODE RATE I NCREASE IN FREQUENCY OF BOWEL MOVEMENTS
5 SOMEINCREASE IN FREQUENCY OF BOWEL MOVEMENT S
6 S LIGHT INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
7 NORMAL , NO INCREASE IN FREQUE NCY OF BOWEL MOVEMENTS
2.How often has the feeling of fatigue or of being tired and worn out been a problem for y ou 
during the last 2 weeks? Please indicate how often the feel ing o f fatigue or tiredness has been a 
probl em for you durin g the l ast 2 weeks by  picking one of the opti ons fro m
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE T IME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
3.How often during the last 2 weeks have y ou fel t frustr ated, impat ient, or res tless? Please 
choose a n opti on from
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT O F THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE O F THE TIME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 94of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4.How often during the last 2 weeks have y ou been u nable to attend school ordo your work 
becaus e of your bowel  probl em? Pl ease ch oose an opti on from
1 ALL OF TH E TIME
2 MOST OF THE TIME
3 A GOOD BIT OF TH ETIME
4 SOME OF THE TIME
5 A LITTLE OF TH E TIM E
6 H ARDLY ANY OF THE TIME
7 NONE OF THE TIME
5.How much of the time during the last 2 weeks have your bowel  movements been loose ? Please 
choose an option from
1 ALL O F THE TIME
2 MOST OF THE TIME
3 A GOOD BIT O FTHE TIME
4 SOME OF THE TIME
5 A LITTLE O F THE TIME
6 HARDLY ANY OF THE T IME
7 NONE OF THE TIME
6.How m uch energy  have y ou had during the l ast 2 wee ks? Please choose an option from
1 NO ENERGY AT ALL
2 VERY LITTLE ENERGY
3 A LITTLE ENERGY
4 SOME ENERGY
5 A M
ODERATE AMOUNT OF ENERGY
6 A LOT OF ENERG Y
7 F ULL OF ENERGY
7.How often dur ing the last 2 weeks did you feel worri ed about the possibilit y of needin g to have 
surgery  because o f your 
bowel  probl em? Please cho ose an option from
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF T HE TI ME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 95of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
8.How ofte n during the last 2 we eks have you had to delay o r cance l a soci al engagement 
because o f your bowel  probl em? Please choose an optio nfrom
1 ALL OF THE TIME
2 MOST OF THE TIM E
3 A GOOD BIT OF THE TIME
4 SOM E OF THE TIME
5 A LITTLE OF THE TIME
6 HARD LY ANY O F THE TIME
7 NONE OF T HE TIME
9.How often during th e last 2 weeks have you been tro ubled by cramps in your abdo men? Please 
choose an option from
1 ALL OF THE TIME
2 MOST OF TH E TIM E
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTL E OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
10.How often duri ng the last 2 weeks have y ou fel t gene rally unwell? Please choose an option 
from
1 A LL OF THE TIME
2 MOST OF THE TIME
3 A GO OD BI T OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY O F THE TI ME
7 NONE OF THE TIME
11.How often during the last 2 weeks have y ou been troubl ed be cause of fear of not finding a 
washroom? Please ch oose an option fro m
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF T HE TIME
4 SOME OF THE TIME
5 A LITTLE OF TH E TIME
6 HARDLY ANY OF THE TIM E
7 NONE OF THE TIME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 96of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
12.How mu ch diff iculty have you had, as a resul t of your bowel problems, do ing leisure or s ports 
activit ies you woul d have liked to h ave d one during the last 2 weeks ? Please choose an option 
from
1 A GREAT DE AL OF D IFFICULTY; ACTIVITIES M ADE IMPOSSIBLE
2 A LOT OF D
IFFICUL TY
3 A FAIR BIT OF DIFFIC ULTY
4 SOME DIFFICULTY
5 A LITTLE DIFFICULTY
6 HAR DLY ANY DIFFICULTY
7 NO DIFFICULTY; THE BOWEL P ROBL EMS DID NOT LIMIT SPORT S OR 
LEISURE ACTIVITIES
13.How often during th e last 2weeks have you been t roubl ed by pain in the abdo men? Pl ease 
choose an option fro m
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BI TOF THE TIME
4 SOME OF THE TIME
5 A LITTL E OF THE TIME
6 HARDLY ANY OF TH E TIME
7 NONE OF THE TIME
14.How often during the last2 weeks have you had probl ems getting a good nig ht’s sleep, or been 
troubled by waking up during the night? Please choose an optio nfrom
1 ALL OF THE TIME
2 MOST OF THE TIM E
3 A GOOD BIT OF THE TIME
4 SOM E OF THE TIME
5 A LITTLE OF THE TIME
6 HARD LY ANY OF THE TIME
NONE OF TH E TIME
15.How often during the last 2 weeks have you felt depr essed or discouraged? Please choose an 
option from
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF T HE TIME
5 A LITTLE OF THE TI ME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 97of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIM E
16.How often during the last 2 weeks have you had to avoid a ttendi ng events where there was no 
washroom close a
thand? Please choose an option fro m
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIM E
5 A LITTLE OF THE TIME
6 HAR DLY ANY OF THE TIME
7 NONE OF THE TIME
17.Overall, in the last 2 weeks, how much o f a problem have you had wit h passing large amounts 
of gas? Pl ease choos e an option from
1 A MAJOR PROBL EM
2 A BIG PROBLEM
3 A SIGNI FICANT PROBLEM
4 SOME TROUBLE
5 A LITTLE TROU BLE
6 HARDLY ANY TROUBLE
7 NO TROU BLE
18.Overall, in the last 2 weeks, how m uch of a probl em have y ou had m ainta i ning or getting to, 
the wei ght y ou woul d like to beat? Please choose an option from
1 A MAJOR PROBLE M
2 A BIG PROBL EM
3 A SIGNIFICANT PROBLEM
4 S OME TROUBLE
5 A LITTLE TROU BLE
6 H ARDLY ANY TROUBLE
7 NO TR OUBLE
19.Many  patients with bowel  problems often have worries and anxiet ies related to thei r illness . 
These include worries abo ut getting cancer, worries about never feel ing any better, and worries 
about having a rel apse. In ge neral, how often during the last 2 wee ks have y ou felt worri ed or 
anxious? Please choose an opti on from
1 ALL OF THE TIME
2 MOST OF T HE TIME
3 A GOOD BIT OF THE TIME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 98of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4 SOME OF THE TIME
5 A LITTLE OF THE TIM E
6 HARDLY ANY OF THE T IME
7 NONE OF THE TIME
20.How much of the time during the last 2 wee ks have y ou been troubled by a feeling of 
abdominal bloating? Please choose an option from
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF TH E TIME
4 SOME O F THE T
IME
5 A LITTLE OF THE T IME
6 HARDLY ANY OF THE TIM E
7 NONE OF THE TIME
21.How often during the last 2 weeks have y ou fel t relaxed and f ree of tensi on? Please choose an 
option from
1 NONE OF THE TIME
2 A LITTLE OF THE TIME
3 SOME OF THE T IME
4 A GOOD BI T OF TH ETIME
5 MOST OF THE TI ME
6 ALMOST ALL OF THE TIME
7 ALL OF THE TIME
22.How m uch of the tim e during the l ast 2 weeks have y ou had a pro blem wi th rectal  bleeding 
with your bowel  movements? Please choose an opti on from
1 ALL OF THE TIME
2 MOST OF THE TIM E
3 A GOOD BIT OF THE TIME
4 S OME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
23.How m uch of the time durin g the last 2 weeks have y ou felt embarrass ed as a r esult of your 
bowel  problem? Please choose an optio n from
1 ALL OF THE TI ME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 99of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4 S OME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF T HE TIME
7 NONE OF THE TIME
24. H ow much o f the time during the last 2 we ekshave you been troubled by a feeling of having to 
go to t he bathroom eve n thoug h your bowels were empt y? Please choose an option from
1 ALL OF THE TIME
2 MOST OF THE T IME
3 A GOOD BIT O F THE TIME
4 SOME OF THE TIM E
5 A LITTLE OF THE TIME
6 HARDLY ANY OF TH E TIME
7 NONE OF THE TIME
25.How much o f the time during the last 2 weeks h ave y oufelt tearful or upset? Please choose an 
option from
1 ALL OF THE TIME
2 MOST OF THE TIM E
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
26.How m uch o f the time during the l ast 2 weeks have y ou been troubl ed by acciden tal soiling of 
your underpa nts? Pl ease choose an option fro m
1 ALL OF THE TIME
2 MOST OF THE T IME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE O F THE TIME
6 HARDLY ANY OF TH E TIME
7 NONE OF THE TIME
27.How much of the t ime dur ing the last 2 weeks ha ve you felt angry as a resu lt of your bowel  
probl em? Please choos e an option fro m
1 ALL OF THE TIME
2 MOST OF T HE TIME
3 A GOOD BIT OF T HE TIM E
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 100of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4 SOME OF THE TI ME
5 A LITTLE OF THE TI ME
6 HARDLY ANY OF THE TIME
7 NONE OF THE T IME
28.To what extent has your bo wel probl emlimited sexual activity during the last 2 weeks? Plea se 
choose an optio n from
1 NOSEX AS A RESULT OF BOWEL DISEASE
2 MAJOR LIMITA TION AS A RE SULT O F BOWEL DISEASE
3 MODER ATE LIMITATION AS A RESULT O F BOWEL DISEASE
4 SOME LIMITATION AS A RESULT OF BOWEL DISEASE
5 A LITTL E LIMIT ATION AS A RESULT OF BOWEL DISE ASE
6 HARDLY ANY L IMITATION A S A RESULT OF BOW EL DISEASE
7 NO LIMITATIO N AS A RESULT OF B OWEL D ISEASE
29.How much of the time during the last 2 weeks have you been troubl ed by nausea or feeling sick 
to your stom ach? Pleas e choos e an option. fro m
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TI ME
4 SOME OF THE TIME
5 A LITTL E OF THE TIM E
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
30.How much of the time durin g the l ast 2 weeks have y ou felt irritable? Please choose an opt ion 
from
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT O F THE TIME
4 SOME OF THE TIME
5 A LITTLE O F THE TIME
6 HARDL Y ANY OF THE TIME
7 NONE OF T HE TIME
31.How often during the past 2 weeks h ave y oufelt a lack of understanding fro m others? Pl ease 
choose an option from
1 ALL OF THE TIM E
2 MOST OF THE TI ME
3 A GOOD BIT OF THE TIME
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 101of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
4 SOME OF THE TIME
5 A LI TTLE O F THE TIME
6 HARDL Y ANY OF THE TIME
7 NONE OF THE TIME
32.How satisfied, happy, or pl eased hav e you been with y our personal  life during the past 2 
week s? Please choose one of the fo llowing opti ons f rom
1 VERY DI SSATISFIED, UNHAP PY MOST OF THE TIME
2 GEN ERALLY DISSATISFIE D, UNH APPY
3 SOMEWHAT DISSATI SFIED, UNHAPPY
4 GENERALLY S ATISFIED, PLEAS ED
5 SATISFIED MOST OF THE TIME, HAPPY
6 VERY SATISFIED M OST OF THE TIME, HAPPY
7 EXTREMELY SAT ISFIED, COULD NOT HAVE BEEN MORE HAPPY OR PLEA SED
Copyright © 1989 McMa ster U niversity, H amilto n, Ontario, Canada .
TheInflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of 
McM aster University (Copyright ©1989, McMaster Unive rsity). The IBDQ has been pr ovided under license from
McMas ter Universi ty and must not be copied, di stributed or used in any way without the pr ior wri tten consent of 
McMaster University. 
Contact the McMaste r Industry Liaison Office at Mc Master University, email: mil o@mcmaster.ca for licensing 
details.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Vedolizumab IV
Study No. Vedolizumab-4004 Page 102 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Appendix J Detailed Description of Amendments to Text
The primary section(s) of the protocol affected by the changes in Amendment No. 04 are indicated. 
The corresponding text has been revised throughout the protocol. 
This protocol amendment is considered as non-substantial as the changes made do not 
significantly or negatively impact the safety or physical or mental integrity of the clinical trial
participants nor the scientific value of the trial. 
Change 1:  
The primary change occurs in Section 5.1.3 Exploratory Objectives:
Initial 
wording:Exploratory objectives are:
Amended 
or new
wording:Exploratory objectives are:
Rationale for Change:
The addition of these exploratory objectives is considered to be non-substantial and does not 
require new subject procedures nor does it alter the main objectives of this trial.CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use OnlyOnct to the Aphe
toable Terms of Used. 
calaltrialtriall
ab
plicab
Applic
nly and Subject
da: For Non-Commercial Use
Takedaale fale forofffededed
perty of Ta
Vedolizumab IV
Study No. Vedolizumab-4004 Page 103 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Section 2.0 STUDY SUMMARY also contains this change. 
Change 2: Added exploratory endpoints corresponding to new objectives 
The primary change occurs in Section 5.2.3 Exploratory Endpoints:
Initial 
wording:The exploratory endpoints are:
Amended 
or new 
wording:The exploratory endpoints are:CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subjebjeable Terms of UseTer
bleo
ms o
bject to the Applicab
keda: For Non-Commercial Use Only and Su
Vedolizumab IV
Study No. Vedolizumab-4004 Page 104 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Rationale for Change:
To add new exploratory endpoints corresponding to new objectives.The addition of exploratory endpoints is consisten t with changes to the exploratory objectives and 
is considered to be a non-substantial cha nge; the additional endpoints do not require new subject
procedures nor do they alter the ma in objectives of this trial.
Section  2.0 STUDY SUMMARY also contains this change.
Change 3:
The primary change occurs in Section  9.1.10: Pouchitis Endoscopy:
Initial 
wording:
Amended 
or new 
wording:
Rationale for Change:
To clarify centr ally read assessments th at correspond to the new exploratory endpoints. This 
change is considered non-substantial because the additional exploratory endpoints do not require 
new subject procedures nor do they alter the main objectives of this trial.CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useand and 
subjectubjec
e
ca
App
ts that cs that
ntialtialbblle
o they theyUse
re Only and Subject to the
r Non-Com
Vedolizumab IV
Study No. Vedolizumab-4004 Page 105 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Added tex
Rationale for Change:
 
.
Change 5:
The primary change occurs in Section  13.1.3 Efficacy  Analysis:
Initial 
wording:Change from baseline in mPDAI, PDAI, IBDQ, and CGQL scores will be analyzed 
using Wilcoxon rank sum tests; the Wilcoxon-Mann-Whitney odds estimator and its 
95% CI will also be presented.
Amended or new 
wording:Change from baseline in mPDAI, PDAI, IBDQ, and CGQL scores will be 
analyzed using Wilcoxon rank sum tests; the Wilcoxon-Mann-Whitney odds 
estimator and its 95% CI will also be presented.
Rationale for Change:CCI
CCICCI
C
CI
CCI
CCI
Property of Takeda: For Non-Commercial Un mPDAmPD
oxon ranxon ra
5% CI w% CIl Use Only and acy Ay Annalnd
PDAI, PDAI, II
the Wilhe W
d.d.ly
lU
m
or Non-Cott o  t h etheUse
ect tohe Applicable Terms of Us
SubjecSubdS u
erty of Takeda: For 
Vedolizumab IV
Study No. Vedolizumab-4004 Page 106 of 107Protocol Incorporating Amendment No. 04 14 September 2020
Rationale for Change:
Change 7: Clarified that prior medication history includes all prior medications for the treatment 
of UC/pouchitis.
The primary change occurs in Section 9.1.2: Demographics, Medical History, and Medication 
History Procedure:
Initial 
wording:In addition, all prior biologic medication history for the treatment of UC/pouchitis, 
with the reason for discontinuation is to be collected for subjects where possible.
Amended or new 
wording:In addition, all prior biologic medication history for the treatment of UC/pouchitis, 
with the reason for discontinuation ,is to be collected for subjects where possible.
Rationale for Change:
This change clarifies the intent of the study  to collect all prior medication for the treatment of 
UC/pouchitis and not just biologics. This clarificati on is considered to be a non-substantial change.
10.Change 8: Corrected acute histologic inflammation descriptors for score of 0 in Appendix E
The primary change occurs in Appendix E The Pouchitis Disease Activity Index (PDAI )Appendix 
EAppendix EAppendix EAppendix EAppendix EAppendix EAppendix E .
Description 
of change:[Added response 0 = None for polymorphic nuclear leukocyte infiltration. Added 
response 0 = 0% added for ulceration per low power field (mean).]CCI
CCICCI
Property of Takeda: For Non-Coms in inAppAp
EEAppeApp
d rrespoesp
ponseponse 0Non
Fal Use Only and Subject to the Applicable Terhe treatme treaTe
and Meand Mca
eatatmmente
r subjr subj eceeA
r the trethe t
ected focted ftt
llectlectal
ficatcationiod
 inflaminflame f Use
erms of U
ommercial UCCC
Vedolizuma b IV
StudyNo. Vedolizuma b-4004 Page 107of 107
Protocol Incorporating Ame ndment No. 0 4 14September 2020
Rationale for Change :
Corrected table to al ign with histo logy scoring us ed in this study and to be con sistent wi th other 
text in theprotocol .  
Change 9:Deleted duplicated text descri bing analysis set for primary  analysis .
The primary  change occurs in Section 13.1.3 Efficacy A nalysis : 
Deleted 
text:The primary efficacy analysis will be based on the full analysis set (FAS) including all 
rando mized su bjects. Analysis will also be pe rformed on the PP populat ionfor 
confirmatory  purposes.
Ration ale for Change :
The same informat ionwas writtentwice withinthe same section of the pro tocol . Deleted one of the 
duplicated statement s.This is an editorial correctio n that does notimpact t he analysis metho ds and 
is a non -substant ial chan ge.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GHH䣕䣶䣷䣦䣻䢢䣘䣧䣦䣱䣮䣫䣼䣷䣯䣣䣤䢯䢶䢲䢲䢶䢢䣒䣴䣱䣶䣱䣥䣱䣮䢢䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢶䢼䢢䣃䢢䣴䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣦䣱䣷 䣤䣮䣧䢯䣤䣮䣫䣰䣦䢮䢢䣲䣮䣣䣥䣧䣤䣱䢯䣥䣱䣰䣶䣴䣱䣮䣮䣧䣦䢢䣲䣪䣣䣵䣧䢢䢶䢢䣵䣶䣷䣦䣻
䣶䣱䢢䣧䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣧䣨䣨䣫䣥䣣䣥䣻䢢䣣䣰䣦䢢䣵䣣䣨䣧䣶䣻䢢䣱䣨䢢䣇䣰䣶䣻䣸䣫䣱䢢䢪䣸䣧䣦䣱䣮䣫䣼䣷䣯䣣䣤䢢䣋䣘䢫 䢢䣫䣰䢢䣶䣪䣧䢢䣶䣴䣧䣣䣶䣯䣧䣰䣶䢢䣱䣨䢢䣲䣱䣷䣥䣪䣫䣶䣫䣵䢢䢪䣇䣃䣔䣐䣇䣕䣖䢫
%LRVWDWLVWLFV$SSURYDO 6HS87&
0HGLFDO$IIDLUV$SSURYDO 6HS87&
3KDUPDFRYLJLODQFH$SSURYDO 6HS87&PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

6HSHS